



(51) International Patent Classification:

C07D 403/06 (2006.01) A61K 31/5375 (2006.01)
 C07D 405/12 (2006.01) A61K 31/4025 (2006.01)
 C07D 413/06 (2006.01) A61K 31/40 (2006.01)
 C07D 211/36 (2006.01) A61K 31/396 (2006.01)
 C07D 211/40 (2006.01) A61P 31/04 (2006.01)
 C07D 211/94 (2006.01)

(21) International Application Number:

PCT/EP2017/069179

(22) International Filing Date:

28 July 2017 (28.07.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16181965.1	29 July 2016 (29.07.2016)	EP
17159942.6	08 March 2017 (08.03.2017)	EP
17163270.6	28 March 2017 (28.03.2017)	EP
P201700452	30 March 2017 (30.03.2017)	ES

(71) Applicant: ABAC THERAPEUTICS, S.L [ES/ES]; Joan XXIII, 10, 08950 ESPLUGUES DE LL (ES).

(72) Inventors: PALOMER BENET, Albert; Almería, 21, 08014 BARCELONA (ES). GARGALLO VIOLA, Domingo; C. Ramoneda, 11, 08940 CORNELLÀ DE LLOBREGAT (ES).

(74) Agent: ZBM PATENTS - ZEA, BARLOCCI & MARKVARDSEN; Pl. Catalunya, 1 2nd floor, 08002 BARCELONA (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS



(57) Abstract: 2-Pyrrolidine phenylhydrazides antibacterial agents The present invention relates to 2-pyrrolidine phenylhydrazide compounds of formula (I), which are selective antibacterials specifically against *Acinetobacter baumannii*. The invention also relates to their therapeutic use as antibacterials, to a process for their preparation and to pharmaceutical compositions containing them.



2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS

This application claims the benefit of the European Patent Application EP16181965.1 filed on 29.07.2016, the European Patent Application EP17159942.6
5 filed on 08.03.2017, the European Patent Application EP17163270.6 filed on 28.03.2017 and the Spanish Patent Application ES 201700452 filed on 30.03.2017.

TECHNICAL FIELD

The present invention relates to new antibacterial agents, particularly to 2-pyrrolidine phenylhydrazide compounds that show selective antibacterial activity
10 against the Gram-negative bacteria *Acinetobacter baumannii*.

BACKGROUND ART

Infections caused by *Acinetobacter baumannii* (*A. baumannii*) bacteria are increasingly recognized as a serious health threat, especially in healthcare
15 facilities, and are associated with increased morbidity, mortality and duration of hospital stay, as well as with high healthcare costs (Giamarellou *et al. Acinetobacter baumannii: a universal threat to public health?* Int. J. Antimicrob. Agents, 2008, 32(2), 106-9; Howard *et al. Acinetobacter baumannii. An emerging opportunistic pathogen. Virulence* 2012, 3(3), 243-250).

20 *A. baumannii* is a rod-shaped Gram-negative bacillus that is aerobic, and non-motile. It behaves as an opportunistic pathogen mainly affecting immunocompromised subjects, for example those having an underlying disease, such as chronic lung disease or diabetes, and those hospitalized for long periods and subjected to multiple invasive procedures.

25 *A. baumannii* is often implicated in nosocomial infections, so it has a high incidence among patients experiencing prolonged hospital stay, and is a particularly relevant source of infections in hospital intensive care units (ICUs). Among the main risk factors for acquiring *A. baumannii* is the use of artificial devices commonly employed in hospital settings, such as dialysis, mechanical ventilation, sutures or
30 catheters, due to the notorious ability of *A. baumannii* to survive for extended periods on environmental surfaces.

A. baumannii can cause infections in virtually every organ system of the human body, including pneumonia, surgical site infections, skin and soft tissue infections, urinary tract infections, post-operative meningitis and catheter-related infections.

5 Hospital-acquired pneumonia is the most common life-threatening hospital-acquired infection, and is mainly associated with the use of mechanical ventilation, known as ventilator associated pneumonia (VAP). VAP infections caused by *Acinetobacter* are between 8% and 35% of total VAP cases.

10 Bloodstream infections (BSI) are also common nosocomial infections, which are also associated with increased morbidity, mortality and duration of hospital stay. Infections caused by *Acinetobacter* correspond to 2% of the total BSI cases, with a particular high incidence in ICU-acquired BSI.

15 Other reported hospital-acquired infections associated with *A. baumannii* are, for example, surgical site infections (SSI) and urinary tract infections, such as catheter-associated urinary tract infections (CAUTI) or hospitalized community-acquired urinary tract infections.

20 *A. baumannii* infections are currently treated with different broad- or semi-broad spectrum antibiotics or combinations, including, for example, the carbapenems imipenem, meropenem and doripenem, which are first choice drugs. However, treatment of *A. baumannii* infections is challenging since it has emerged as a highly drug-resistant pathogen, especially carbapenem-resistant, and therefore other alternative broad-spectrum antibacterials are also used in therapy, such as polymyxins (colistin, polymyxin E and polymyxin B), tigecycline, tetracyclines (minocycline and doxycycline) or aminoglycosides (amikacin and tobramycin). None of the currently used
25 treatments are specific for *A. baumannii*.

30 The use of such broad-spectrum antibacterials entails important drawbacks, since they have a substantial impact on the normal flora, potentially diminishing the immunologic function of microbiota and potentially generating treatment-induced co-infections caused by resistant strains, as disclosed for example in Jernberg *et al.* *Long-term impacts of antibiotic exposure on the human intestinal microbiota*, Microbiology, 2010, 156(Pt 11), 3216-3223.

 Moreover, in a retrospective study performed with 26,107 patients, it was concluded that the use of broad-spectrum antibiotics may have a relationship with the development of irritable bowel syndrome (IBS), as disclosed in Villarreal *et al.* *Use of*

broad-spectrum antibiotics and the development of irritable bowel syndrome, WMJ, 2012, 111(1), 17-20.

As previously commented, when broad-spectrum antibiotics are used, not only the pathogenic microorganism, but any other microorganisms present in the treated subject (be either human or animal) may develop resistance. This latter may happen if antibiotic is moderately active but not lethal for it. Moreover, it is known in the art that when a microorganism develops a resistance to a drug is able to transfer such resistance to other members of its specie or even transfer this resistance to other species, this is known as Horizontal Gene Transfer (HGT), as disclosed in Wintersdorff, *et al. Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer*, Front Microbiol. 2016, 7:173. Consequently, it is an advantage of pathogen-specific treatment that generation of resistance in the pathogenic species does not happen by this two-stage process, namely, first producing in other microorganisms and then transfer by HGT to pathogenic species.

In contrast, treatments using pathogen-specific antibacterials that kill exclusively the infecting bacteria would minimize the impact on normal flora and would avoid the selection of resistant strains of non-infecting bacteria of microbiota, thus minimizing any treatment-induced co-morbidities and reducing the Horizontal Gene Transfer of resistance between species.

The only antibacterial agents selective for *Acinetobacter baumannii* disclosed so far in the state of the art are a series of arylhydrazides containing a 2-pyridone moiety, as disclosed in the international patent application WO2016/016291-A1.

Therefore, it would be desirable to provide novel compounds which are selective antibacterial agents against *Acinetobacter baumannii* bacteria, to thus increase the number of selective drugs currently available, which are both effective for treating the life-threatening infections caused by *A. baumannii* and highly selective for this bacteria, in order to avoid the disadvantages associated to the non-selective broad-spectrum antibiotics currently used in therapy.

OBJECT OF THE INVENTION

The object of the present invention is a compound of formula (I) as defined below.

A second aspect of the present invention relates to the compound of formula (I) for use as a medicament.


A third aspect of the present invention relates to a compound of formula (I) for use as antibacterial agent, particularly for treating or preventing *A. baumannii* infections.

A fourth aspect of the present invention relates to a pharmaceutical composition comprising a compound of formula (I) and at least one pharmaceutically acceptable excipient and/or carrier.

A fifth aspect of the present invention relates to a process for preparing compounds of formula (I).

DETAILED DESCRIPTION OF THE INVENTION

In a first aspect, the present invention relates to a compound of formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof,

wherein

R_1 and R_2 are independently selected from hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl and hydroxy C_{1-4} alkyl;

R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkoxy, halo C_{1-4} alkoxy, $-OC_{3-6}$ cycloalkyl C_{0-4} alkyl, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{1-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-OCOR_{11}$, $-OS(O_2)R_{11}$, $-NR_{11}R_{12}$, $-NR_{11}COR_{12}$, $-NR_{11}CO_2R_{12}$, $-NR_{11}S(O_2)R_{12}$, $-OCONR_{11}R_{12}$, $-CONR_{11}R_{12}$, $-S(O_2)NR_{11}R_{12}$, $-S(O_2)R_{11}$, $-CN$ and $-CO_2R_{11}$; or two of R_3 to R_7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl or halo C_{1-4} alkyl;

R_8 is selected from $-OH$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-C(O)C_{3-6}$ cycloalkyl C_{0-2} alkyl, $-CONR_{13}R_{14}$, $-C(NR_{15})NR_{11}R_{12}$ and $-CO_2R_{11}$;

R_9 is selected from hydrogen, C_{1-4} alkyl and halo C_{1-4} alkyl;

n is 0, 1, 2 or 3;

- each R_{10} , if present, is independently selected from $-OH$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-4} alkoxy C_{1-6} alkyl, $-OC_{3-6}$ cycloalkyl C_{0-4} alkyl, $-SR_{11}$, $-NR_{11}R_{12}$, $-OCOR_{11}$, $-OS(O_2)R_{11}$, $-NR_{11}COR_{12}$, $-NR_{11}CO_2R_{12}$, $-NR_{11}S(O_2)R_{12}$, $-OCONR_{11}R_{12}$, $-CN$, phenyl, 5- or 6-membered heteroaryl ring comprising 1 or 2 heteroatoms selected from N, O and S; wherein said phenyl and said heteroaryl ring may be optionally substituted by one or more C_{1-4} alkyl or halo C_{1-4} alkyl; or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to a common carbon atom form a spiro C_{3-6} cycloalkyl, or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl, halo C_{1-4} alkyl and halogen;
- each R_{11} and R_{12} are independently selected from hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl and C_{3-6} cycloalkyl C_{0-4} alkyl;
- each R_{13} and R_{14} are independently selected from hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl and Het $_{3-6}$, wherein each C_{1-4} alkyl and C_{3-6} cycloalkyl C_{0-4} alkyl may optionally be substituted by one or more R_{16} , and wherein each C_{1-4} alkyl may optionally be substituted by one or more Het $_{3-6}$; or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl, halo C_{1-4} alkyl and C_{2-5} acyl;
- R_{15} is selected from hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, $-CN$, $-CONR_{11}R_{12}$, $-S(O_2)R_{11}$, $-SOR_{11}$ and $-S(O_2)NR_{11}R_{12}$;
- each R_{16} is independently selected from alkyl, halogen, $-CN$, $-CO_2R_{11}$, $-OR_{11}$, $-SR_{11}$, $-NR_{17}R_{18}$, $-CONR_{17}R_{18}$ and $-OCOR_{11}$;
- Het $_{3-6}$ is a 3- to 6-membered saturated monocyclic heterocyclic ring containing one heteroatom selected from O, S and N, wherein said ring is bonded to the rest of the molecule through any available C atom and wherein said ring can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl or halo C_{1-4} alkyl; and
- each R_{17} and R_{18} are independently selected from hydrogen, C_{1-4} alkyl and halo C_{1-4} alkyl, or R_{17} and R_{18} form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and halo C_{1-4} alkyl;
- and wherein the following products are excluded:

- 1,2-pyrrolidinedicarboxylic acid, 1-(1,1-dimethylethyl) ester, 2-(2-phenylhydrazide), (2S)-,
- 1,2-pyrrolidinedicarboxylic acid, 1-(1,1-dimethylethyl) ester, 2-(1-methyl-2-phenylhydrazide), (2S)-,
- 5 1,2-pyrrolidinedicarboxylic acid, 4-mercapto-, 1-(1,1-dimethylethyl) ester, 2-[2-[3-(aminosulfonyl)phenyl]hydrazide], (2S,4S)-,
- 1,2-pyrrolidinedicarboxylic acid, 4-mercapto-, 1-(1,1-dimethylethyl) ester, 2-[2-(3-carboxyphenyl)hydrazide], (2S,4S)-,
- 1,2-pyrrolidinedicarboxylic acid, 4-mercapto-, 1-(1,1-dimethylethyl) ester, 2-[2-[2-
- 10 (trifluoromethyl)phenyl]hydrazide], (2S,4S)-, and
- 1,2-pyrrolidinedicarboxylic acid, 4-mercapto-, 1-(1,1-dimethylethyl) ester, 2-[2-[2-chloro-5-(trifluoromethyl)phenyl]hydrazide], (2S,4S)-.

The authors of the present invention have developed a group of

15 phenylhydrazide compounds containing a 2-pyrrolidine moiety as depicted in formula (I) that, surprisingly, show selective antibacterial activity against the Gram-negative bacteria *Acinetobacter baumannii* (*A. baumannii*), providing therefore a new and safer therapeutic tool for treating the infections caused by this bacteria, while avoiding the damage to the intestinal flora and multiple resistances involved with the treatment with

20 the broad-spectrum antibacterials.

Moreover, not only the compounds of formula (I) are highly active and selective antibacterials against *A. baumannii*, as determined in *in vitro* assays, but they are also highly stable in blood plasma, so they are expected to maintain their antibacterial activity *in vivo*, as well.

25 The following compounds are excluded from the first aspect of the present invention:

- 1,2-pyrrolidinedicarboxylic acid, 1-(1,1-dimethylethyl) ester, 2-(2-phenylhydrazide), (2S)- (CAS 474316-85-3)
 - 1,2-Pyrrolidinedicarboxylic acid, 1-(1,1-dimethylethyl) ester, 2-(1-methyl-2-phenylhydrazide), (2S)- (CAS 1361235-82-6)
 - 1,2-Pyrrolidinedicarboxylic acid, 4-mercapto-, 1-(1,1-dimethylethyl) ester, 2-[2-[3-(aminosulfonyl)phenyl]hydrazide], (2S,4S)- (CAS 1188957-98-3)
 - 1,2-Pyrrolidinedicarboxylic acid, 4-mercapto-, 1-(1,1-dimethylethyl) ester, 2-[2-(3-carboxyphenyl)hydrazide], (2S,4S)- (CAS 1188958-01-1)
- 30

- 1,2-Pyrrolidinedicarboxylic acid, 4-mercapto-, 1-(1,1-dimethylethyl) ester, 2-[2-(trifluoromethyl)phenyl]hydrazide], (2S,4S)- (CAS 1188958-02-2)
- 1,2-Pyrrolidinedicarboxylic acid, 4-mercapto-, 1-(1,1-dimethylethyl) ester, 2-[2-[2-chloro-5-(trifluoromethyl)phenyl]hydrazide], (2S,4S)- (CAS 1188958-04-4)

5 These compounds have been disclosed in the following prior art documents: Liu *et al.*, J. Med. Chem., 2012, 55(5), 1868-1897 (compounds 474316-85-3 and 1361235-82-6) and CN101525336-A (compounds 1188957-98-3, 1188958-01-1, 1188958-02-2 and 1188958-04-4). These compounds are disclosed only as reaction intermediates, but their medical use is not disclosed or suggested in the prior art.

10

Definitions

Within the meaning of the present invention, the term C₁₋₆alkyl, as a group or part of a group, means a straight or branched alkyl chain which contains from 1 to 6 carbon atoms and includes, among others, the groups methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, *n*-pentyl, isopentyl or *n*-hexyl. Similarly, the term C₁₋₄alkyl, as a group or part of a group, means a straight or branched alkyl chain which contains from 1 to 4 carbon atoms and is a subgroup of C₁₋₆alkyl which includes the groups methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl and *tert*-butyl. Similarly, the term C₁₋₂alkyl means an alkyl chain which contains 1 or 2 carbon atoms and includes the groups methyl and ethyl.

20

Halogen or its abbreviation halo means fluoro, chloro, bromo or iodo.

A haloC₁₋₆alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C₁₋₆alkyl group with one or more halogen atoms (i.e. fluoro, chloro, bromo or iodo), which can be the same or different. Examples include, among others, the groups fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2-fluoropropyl, 3-fluoropropyl, 2,2-difluoropropyl, 2,3-difluoropropyl, 2-chloropropyl, 3-chloropropyl, 2,3-dichloropropyl, 4-fluorobutyl, 4-chlorobutyl, 4-bromobutyl, nonafluorobutyl, 5-fluoropentyl, 5-chloropentyl, 5-bromopentyl, 5-iodopentyl, undecafluoropentyl, 6-fluorohexyl, 6-chlorohexyl, 6-bromohexyl, 6-iodohexyl. Similarly, the haloC₁₋₄alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C₁₋₄alkyl group with one or more halogen atoms (i.e. fluoro, chloro, bromo or iodo), which can be the same or different, and is a subgroup of haloC₁₋₆alkyl. Examples include, among others, the groups fluoromethyl, difluoromethyl,

35

trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2-fluoropropyl, 3-fluoropropyl, 2,2-difluoropropyl, 2,3-difluoropropyl, 2-chloropropyl, 3-chloropropyl, 2,3-dichloropropyl, 4-fluorobutyl, 4-chlorobutyl, 4-bromobutyl and nonafluorobutyl.

A hydroxyC₁₋₆alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C₁₋₆alkyl group with one or more hydroxy groups. Examples include, among others, the groups hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 2,3-dihydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, 2-hydroxybutyl, 1-hydroxybutyl, 5-hydroxypentyl, 4-hydroxypentyl, 3-hydroxypentyl, 2-hydroxypentyl, 1-hydroxypentyl, 6-hydroxyhexyl, 5-hydroxyhexyl, 4-hydroxyhexyl, 3-hydroxyhexyl, 2-hydroxyhexyl, and 1-hydroxyhexyl. Similarly, a hydroxyC₁₋₄alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C₁₋₄alkyl group with one or more hydroxy groups, and is a subgroup of the hydroxyC₁₋₆alkyl group. Examples of hydroxyC₁₋₄alkyl group include, for example, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 2,3-dihydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, 2-hydroxybutyl and 1-hydroxybutyl.

A C₂₋₅acyl group means a group of formula -C(O)C₁₋₄alkyl, wherein the C₁₋₄alkyl moiety has the same meaning as described above. Examples include, among other, acetyl, propanoyl, n-butanoyl, sec-butanoyl, tert-butanoyl, or n-pentanoyl. Similarly, a C₂₋₃acyl group means a group of formula -C(O)C₁₋₂alkyl, wherein the C₁₋₂alkyl moiety has the same meaning as described above. Examples include acetyl and propanoyl.

A C₁₋₆alkoxy group, as a group or part of a group, means a group of formula -OC₁₋₆alkyl, wherein the C₁₋₆alkyl moiety has the same meaning as described above. Examples include methoxy, ethoxy, propoxy, isopropoxy, *n*-butoxy, isobutoxy, sec-butoxy, *tert*-butoxy, *n*-pentoxy, isopentoxy, neopentoxy, or *n*-hexoxy, among others. Similarly, a C₁₋₄alkoxy group, as a group or part of a group, means a group of formula -OC₁₋₄alkyl, wherein the C₁₋₄alkyl moiety has the same meaning as described above and is a subgroup of the C₁₋₆alkoxy which includes, for example, methoxy, ethoxy, propoxy, isopropoxy, *n*-butoxy, isobutoxy, sec-butoxy and *tert*-butoxy.

A C₁₋₄alkoxyC₁₋₄alkoxy group means a group resulting from the replacement of one hydrogen atom from a C₁₋₄alkoxy group with one C₁₋₄alkoxy group,

as defined above. Examples include, among others, methoxymethoxy, methoxy-1-ethoxy, methoxy-2-ethoxy, ethoxymethoxy, ethoxy-1-ethoxy, ethoxy-2-ethoxy, methoxy-3-propoxy, ethoxy-3-propoxy, and propoxy-3-propoxy.

A haloC₁₋₄alkoxy group means a group resulting from the replacement of one or more hydrogen atoms from a C₁₋₄alkoxy group with one or more halogen atoms (i.e. fluoro, chloro, bromo or iodo), which can be the same or different. Examples include, among others, the groups fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2-iodoethoxy, 2-fluoropropoxy, 3-fluoropropoxy, 2,2-difluoropropoxy, 2,3-difluoropropoxy, 2-chloropropoxy, 3-chloropropoxy, 2,3-dichloropropoxy, 4-fluorobutoxy, 4-chlorobutoxy, 4-bromobutoxy or nonafluorobutoxy.

A C₁₋₄alkoxyC₁₋₆alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C₁₋₆alkyl group with one or more C₁₋₄alkoxy groups as defined above, which can be the same or different. Examples include, among others, the groups methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl, isobutoxymethyl, *sec*-butoxymethyl, *tert*-butoxymethyl, dimethoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl, 1,2-diethoxyethyl, 1-butoxyethyl, 2-*sec*-butoxyethyl, 3-methoxypropyl, 2-butoxypropyl, 1-methoxy-2-ethoxypropyl, 3-*tert*-butoxypropyl, 4-methoxybutyl, 5-methoxypentyl, 4-ethoxypentyl and 2-methoxy-3-methylpenyl. Similarly, a C₁₋₄alkoxyC₁₋₄alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C₁₋₄alkyl group with one or more C₁₋₄alkoxy groups as defined above, and is a subgroup of the C₁₋₄alkoxyC₁₋₆alkyl group. Examples of C₁₋₄alkoxyC₁₋₄alkyl include, among others, methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl, isobutoxymethyl, *sec*-butoxymethyl, *tert*-butoxymethyl, dimethoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl, 1,2-diethoxyethyl, 1-butoxyethyl, 2-*sec*-butoxyethyl, 3-methoxypropyl, 2-butoxypropyl, 1-methoxy-2-ethoxypropyl, 3-*tert*-butoxypropyl and 4-methoxybutyl.

A C₃₋₆cycloalkyl group, as a group or as a part of a group, means a saturated, monocyclic, hydrocarbon ring group comprising 3 to 6 carbon atoms, which can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl, C₁₋₄alkoxy and halogen, i.e., one or more hydrogen atoms of the ring can be replaced by a C₁₋₄alkyl, a C₁₋₄alkoxy or a halogen. When there is more than one

substitution, the substituents can be the same or different. Examples of C₃₋₆cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

A C₃₋₆cycloalkylC₁₋₄alkyl group, as a group or as a part of a group, means a group resulting from the replacement of one hydrogen atom from a C₁₋₄alkyl group with one C₃₋₆cycloalkyl group, as defined above. Examples include, among
 5 others, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopropylethyl, 2-cyclopropylpropyl, 3-cyclopentylpropyl and 4-cyclopentylbutan-2-yl. Similarly, a C₃₋₆cycloalkylC₁₋₂alkyl group, as a group or as a part of a group, means a group resulting from the replacement of one hydrogen atom from a C₁₋₂alkyl group with
 10 one C₃₋₆cycloalkyl group, as defined above, and is a subgroup of the C₃₋₆cycloalkylC₁₋₄alkyl group, including among other the following examples: cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, and cyclohexylethyl. Thus, for example, the –C(O)C₃₋₆cycloalkylC₁₋₂alkyl group means a group resulting from the replacement of one
 15 hydrogen atom from a –C(O)C₁₋₂alkyl group with one C₃₋₆cycloalkyl group. Analogously, the –OC₃₋₆cycloalkylC₁₋₄alkyl group means a group resulting from the replacement of one hydrogen atom from a –OC₁₋₄alkyl group with one C₃₋₆cycloalkyl group.

The term C₀alkyl indicates that the alkyl group is absent.

Thus, for example, the term C₃₋₆cycloalkylC₀₋₄alkyl includes C₃₋₆cycloalkyl and C₃₋₆cycloalkylC₁₋₄alkyl, as defined above, and the term C₃₋₆cycloalkylC₀₋₂alkyl includes C₃₋₆cycloalkyl and C₃₋₆cycloalkylC₁₋₂alkyl. Analogously, the term –C(O)C₃₋₆cycloalkylC₀₋₂alkyl includes –C(O)C₃₋₆cycloalkyl and –C(O)C₃₋₆cycloalkylC₁₋₂alkyl and the term –OC₃₋₆cycloalkylC₀₋₄alkyl includes –OC₃₋₆cycloalkyl and –OC₃₋₆cycloalkylC₁₋₄alkyl.
 20

Likewise, the term C₁₋₄alkoxyC₀₋₆alkyl includes C₁₋₄alkoxy and C₁₋₄alkoxyC₁₋₆alkyl as defined above.
 25

An “oxo” group means =O.

A “methylene” group means –CH₂–.


The term “saturated” relates to groups that do not have any double or
 30 triple bonds.

Any carbon atom as well as any heteroatom with unsatisfied valences in the formulas and schemes depicted in the present description is assumed to have the sufficient number of hydrogen atoms to satisfy the valences.

The expression “optionally substituted by one or more” means that a
 35 group may be substituted with one or more substituents, preferably 1, 2, 3 or 4, more


preferably 1, 2 or 3, and more preferably 1 or 2 substituents, provided that the group has enough positions available susceptible of being substituted, i.e., enough hydrogen atoms available for replacement by a substituent. When more than one substituent are present, they may be the same or different and may be located on any available position.

In the compounds of formula (I), the variable point of attachment depicted for the R_{10} substituents means that, if present, each R_{10} may be attached to any one of the three available positions of the pyrrolidine ring susceptible of being substituted, i.e., having hydrogen atoms available for replacement by a R_{10} , as shown with an asterisk (*) in the figure below. Each of the three marked carbon atoms of the pyrrolidine ring has two hydrogens, so each of the marked carbon atoms can have up to two R_{10} substituents, or two R_{10} attached to a common carbon may form an oxo group, or two R_{10} attached to a common carbon atom form a spiro C_{3-6} cycloalkyl. If more than one R_{10} is present, unless they form an oxo group or a spiro cycloalkyl, they are preferably not attached to the same carbon atom of the pyrrolidine ring.




A 5- or 6- membered heteroaryl ring comprising 1 or 2 heteroatoms selected from N, O and S, as used in the present invention, includes, for example, pyridine, pyridazine, pyrimidine, pyrazine, furan, thiophene, pyrrole, imidazole and thiazole rings.

In the definition of formula (I) above, two groups of R_3 to R_7 attached to adjacent carbon atoms of the phenyl ring may be connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O. Said cycloalkyl is, therefore, fused to the phenyl ring in formula (I); examples of said fused cycloalkyl rings include, among others, the following:



In the definition of formula (I) above two R₁₀ attached to adjacent carbon atoms of the pyrrolidine ring may be connected to form a 3- to 6-membered cycloalkyl. Said cycloalkyl is, therefore, fused to the pyrrolidine ring in formula (I); examples of said fused cycloalkyl rings include the following:



In the definition of formula (I) above R₁₃ and R₁₄ may form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted with one or more substituents independently selected from C₁₋₄alkyl, haloC₁₋₄alkyl and C₂₋₅acyl, i.e., one or more hydrogen atoms of the ring can be replaced by a C₁₋₄alkyl, haloC₁₋₄alkyl or C₂₋₅acyl, the substitution may be

on a C-atom or a N-atom, if present. Examples of such heterocycles include azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine, among other.

Similarly, R₁₇ and R₁₈ may form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted with one or more substituents independently selected from C₁₋₄alkyl and haloC₁₋₄alkyl, i.e., one or more hydrogen atoms of the ring can be replaced by a C₁₋₄alkyl or haloC₁₋₄alkyl, the substitution may be on a C-atom or a N-atom, if present. Examples of such heterocycles include azetidine, pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine, among other.

Thorough the description of the current invention, it is understood that when any variable (e.g. C₁₋₆alkyl, C₁₋₄alkyl, C₁₋₄alcoxy, etc.) occurs more than once in a compound of formula (I), its definition on each occurrence is independent of its definition at every each other occurrence, so that the variable may be the same or different on each occasion.

Likewise, when a variable group, such as R₁₀, R₁₁ or R₁₂, occurs more than once in a compound of formula (I), its definition on each occurrence is independent of its definition at every each other occurrence, so that the variable group is independently selected from its possible meanings at each occurrence, and may have the same meaning or different meaning on each occasion. It may be indicated by the expression "each independently selected from".

Similarly, the term "independently selected from" applied to the definition of a group of different variable groups (e.g. R₃, R₄, R₅, R₆ and R₇), means that the definition of each variable of that group is independently selected from the definition of the other variable of the same group, and may have the same meaning or different meanings.

Compounds of the invention

Also included within the scope of the invention are the pharmaceutically acceptable salts, solvates, isotopes, stereoisomers and polymorphs of compounds of formula (I). Thus, any reference to a compound of formula (I) throughout the present specification includes a reference to any pharmaceutically acceptable salt, solvate, isotope or polymorph of such compound of formula (I).

The compounds of formula (I) have one or more asymmetric or chiral centres and therefore exist in different stereoisomeric forms. It is intended that all

stereoisomeric forms of the compounds of formula (I), including diastereomers, enantiomers, as well as mixtures thereof such as racemic mixtures, form part of the invention.

5 The compounds of the present invention contain basic nitrogen atoms and may, therefore, form salts with organic or inorganic acids. The term “pharmaceutically acceptable salts” as used herein encompasses any salt with no limitation on the type of salt that can be used, provided that these are acceptable for administration to a patient, meaning that they do not induce undue toxicity, irritation, allergic responses, or the like. Pharmaceutically acceptable salts are well known in the
10 art.

For example, the pharmaceutically acceptable salts suitable for being used in the present invention include those derived from the following acids: hydrobromic, hydrochloric, phosphoric, nitric, sulfuric, acetic, adipic, aspartic, benzenesulfonic, benzoic, citric, ethanesulfonic, formic, fumaric, glutamic, lactic,
15 maleic, malic, malonic, mandelic, methanesulfonic, 1,5-naphthalendisulfonic, oxalic, pivalic, propionic, *p*-toluenesulfonic, succinic and tartaric acids, and the like. Hydrochloric acid is preferred.

The salts of a compound of formula (I) can be obtained, for example, during the final isolation and purification of the compounds of the invention, or can be
20 prepared by treating a compound of formula (I) with a sufficient amount of the desired acid to give the salt in the conventional manner.

The term “solvates” as used herein encompasses a combination of a compound of formula (I) with solvent molecules, bonded by a non-covalent bond. Well known solvent molecules which are able to form solvates include water, alcohols and
25 other polar organic solvents. When the solvate is formed with water, it is also known as a hydrate.

The term “isotopes” as used herein encompasses any isotopically-labelled form of the compounds of formula (I), wherein one or more atoms are replaced by an atom having the same atomic number, but an atomic mass or mass number
30 different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, such as ²H and ³H, carbon, such as ¹¹C, ¹³C and ¹⁴C, chlorine, such as ³⁶Cl, fluorine, such as ¹⁸F, iodine, such as ¹²³I and ¹²⁵I, nitrogen, such as ¹³N and ¹⁵N, oxygen, such as ¹⁵O, ¹⁷O and ¹⁸O, and sulfur, such as ³⁵S. Those isotopically-labelled
35 compounds are useful, for example, in metabolic or kinetic studies, particularly those

labelled with ^2H , ^3H , and ^{14}C . Moreover, substitution with heavier isotopes such as deuterium, ^2H , may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements.

5 Isotopically-labelled compounds of the invention can generally be prepared by processes analogous to those described herein, by using an appropriate isotopically-labelled reagent in place of the non-labelled reagent otherwise employed.

 The compounds of formula (I) may exist in different physical forms, i.e. amorphous and crystalline forms. Moreover, the compounds of the invention may have
10 the ability to crystallize in more than one form, a characteristic which is known as polymorphism. Polymorphic forms can be distinguished by various physical properties well known in the art such as X-ray diffraction pattern, melting point or solubility. All such physical forms of the compounds of formula (I), including all polymorphic forms ("polymorphs") are included within the scope of the invention.

15 Furthermore, any formula given herein is also intended to represent the corresponding tautomeric forms. "Tautomer" refers to alternate forms of a molecule that differ in the position of a proton. Examples include, among others, the amide-imidic acid, amine-imine and keto-enol forms.

 The first aspect of the invention is further defined by some specific and
20 preferred embodiments as disclosed below.

 In one embodiment, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein:

R_1 and R_2 are independently selected from hydrogen and C_{1-4} alkyl;

R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-\text{OH}$, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, $-\text{NR}_{11}\text{R}_{12}$, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-\text{CONR}_{11}\text{R}_{12}$, $-\text{SO}_2-\text{NR}_{11}\text{R}_{12}$, and halo C_{1-4} alkoxy, or two of
25 R_3 to R_7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl;

30 R_8 is selected from $-\text{OH}$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-\text{C}(\text{O})\text{C}_{3-6}$ cycloalkyl C_{0-2} alkyl, $-\text{CONR}_{13}\text{R}_{14}$ and $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$;

R_9 is selected from hydrogen and C_{1-4} alkyl;

n is 0, 1, 2 or 3;

each R_{10} , if present, is independently selected from $-OH$, halogen, $C_{1-6}alkyl$, $C_{1-4}alkoxyC_{0-6}alkyl$, $-SR_{11}$ and $-NR_{11}R_{12}$; or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from $C_{1-4}alkyl$ and halogen;

each R_{11} and R_{12} are independently selected from hydrogen and $C_{1-4}alkyl$;

each R_{13} and R_{14} are independently selected from hydrogen and $C_{1-4}alkyl$, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from $C_{1-4}alkyl$ and $C_{2-5}acyl$; and

R_{15} is selected from hydrogen, $C_{1-6}alkyl$, $haloC_{1-6}alkyl$, $-CN$, $-CONR_{11}R_{12}$, $-SO_2-R_{11}$, $-SO-R_{11}$ and $-SO_2-NR_{11}R_{12}$.

In one embodiment, the invention relates to the compounds of formula (I) wherein the phenyl ring has one, two or three substituents, i.e., at least one of R_3 to R_7 is not hydrogen and at least two of R_3 to R_7 are hydrogen.

In another embodiment, the invention relates to the compounds of formula (I) wherein R_1 and R_2 are independently selected from hydrogen and methyl.

In another embodiment, the invention relates to the compounds of formula (I) wherein R_1 and R_2 are hydrogen.

In another embodiment, the invention relates to the compounds of formula (I) wherein one of R_1 and R_2 is hydrogen and the other is $C_{1-4}alkyl$, preferably is methyl.

In another embodiment, the invention relates to the compounds of formula (I) wherein R_1 and R_2 are $C_{1-4}alkyl$, which are the same or different, preferably R_1 and R_2 are the same $C_{1-4}alkyl$, and more preferably R_1 and R_2 are both methyl.

In another embodiment, the invention relates to the compounds of formula (I) wherein R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-OH$, halogen, $C_{1-6}alkyl$, $C_{3-6}cycloalkylC_{0-4}alkyl$, $-NR_{11}R_{12}$, $haloC_{1-6}alkyl$, $hydroxyC_{1-6}alkyl$, $C_{1-4}alkoxyC_{0-6}alkyl$, $C_{1-4}alkoxyC_{1-4}alkoxy$, $-CONR_{11}R_{12}$, $-SO_2-NR_{11}R_{12}$ and $haloC_{1-4}alkoxy$; preferably are independently selected from hydrogen, $-OH$, halogen, $C_{1-6}alkyl$, $haloC_{1-6}alkyl$, $C_{1-4}alkoxyC_{0-6}alkyl$, $C_{1-4}alkoxyC_{1-4}alkoxy$, $-SO_2-NR_{11}R_{12}$ and $haloC_{1-4}alkoxy$; more preferably are independently selected from hydrogen, halogen, $C_{1-4}alkyl$, $haloC_{1-4}alkyl$, $C_{1-4}alkoxy$, $-SO_2-NR_{11}R_{12}$ and $haloC_{1-4}alkoxy$; and still more

preferably R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy and $-\text{SO}_2-\text{NH}_2$.

In a preferred embodiment, the invention relates to the compounds of formula (I) wherein R_5 is selected from $-\text{OH}$, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, $-\text{NR}_{11}\text{R}_{12}$, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-\text{CONR}_{11}\text{R}_{12}$, $-\text{SO}_2-\text{NR}_{11}\text{R}_{12}$ and halo C_{1-4} alkoxy; preferably is selected from $-\text{OH}$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-\text{SO}_2-\text{NR}_{11}\text{R}_{12}$ and halo C_{1-4} alkoxy; more preferably is selected from halogen, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, $-\text{SO}_2-\text{NR}_{11}\text{R}_{12}$ and halo C_{1-4} alkoxy; still more preferably is selected from fluoro, chloro, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy and $-\text{SO}_2-\text{NH}_2$; and still more preferably R_5 is fluoro; R_3 is selected from hydrogen, halogen and C_{1-6} alkyl; more preferably R_3 is selected from hydrogen, halogen and C_{1-4} alkyl, still more preferably R_3 is selected from hydrogen, fluoro, chloro, ethyl and methyl; and still more preferably R_3 is hydrogen; and R_4 , R_6 and R_7 are hydrogen.

In another preferred embodiment, the invention relates to the compounds of formula (I) wherein R_4 and R_6 are independently selected from $-\text{OH}$, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, $-\text{NR}_{11}\text{R}_{12}$, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-\text{CONR}_{11}\text{R}_{12}$, $-\text{SO}_2-\text{NR}_{11}\text{R}_{12}$ and halo C_{1-4} alkoxy; preferably are selected from $-\text{OH}$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl and halo C_{1-4} alkoxy; more preferably are selected from halogen, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy and halo C_{1-4} alkoxy; and still more preferably are selected from fluoro, chloro, methyl, ethyl, methoxy, ethoxy, trifluoromethyl and trifluoromethoxy; and R_3 , R_5 and R_7 are hydrogen.

In another preferred embodiment two of R_3 to R_7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl; and preferably the other three of R_3 to R_7 are hydrogen; more preferably R_4 and R_5 are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl, and R_3 , R_6 and R_7 are hydrogen; more preferably R_4 and R_5 are connected to form a saturated 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O atoms, said cycloalkyl can be optionally substituted by one or more C_{1-}

alkyl, and R_3 , R_6 and R_7 are hydrogen; and still more preferably R_4 and R_5 are connected to form a 1,4-dioxane, and R_3 , R_6 and R_7 are hydrogen.

In another embodiment, the invention relates to the compounds of formula (I) wherein R_8 is selected from selected from $-\text{OH}$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{0-4}\text{alkyl}$, $\text{C}_{2-5}\text{acyl}$, $-\text{CONR}_{13}\text{R}_{14}$ and $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and $\text{C}_{1-4}\text{alkyl}$, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, preferably selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from $\text{C}_{1-4}\text{alkyl}$ and $\text{C}_{2-5}\text{acyl}$; more preferably R_8 is selected from $-\text{OH}$, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkylC}_{1-4}\text{alkyl}$, $\text{C}_{2-5}\text{acyl}$, $-\text{CONR}_{13}\text{R}_{14}$ and $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and $\text{C}_{1-4}\text{alkyl}$, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, preferably said heterocycle is piperazinyl or morpholinyl, said heterocycle can be optionally substituted by one or more substituents independently selected from $\text{C}_{1-4}\text{alkyl}$ and $\text{C}_{2-3}\text{acyl}$;

In another embodiment, the invention relates to the compounds of formula (I) wherein R_9 is $\text{C}_{1-4}\text{alkyl}$, preferably is methyl.

In another embodiment, the invention relates to the compounds of formula (I) wherein R_9 is hydrogen.

In another embodiment, the invention relates to the compounds of formula (I) wherein n is 1, 2 or 3, preferably is 1 or 2, and each R_{10} is independently selected from halogen, $\text{C}_{1-4}\text{alkyl}$ and $-\text{NR}_{11}\text{R}_{12}$; or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, more preferably a 3- to 5-membered cycloalkyl, and still more preferably a 3-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from $\text{C}_{1-4}\text{alkyl}$ and halogen; more preferably, each R_{10} is independently selected from chloro, fluoro, methyl, ethyl, and $-\text{NH}_2$, or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3-membered cycloalkyl.

In another embodiment, the invention relates to the compounds of formula (I) wherein n is 0.

In a preferred embodiment, the invention relates to the compounds of formula (I) wherein:

- R_1 and R_2 are independently selected from hydrogen and C_{1-4} alkyl; preferably from hydrogen and methyl, and more preferably R_1 and R_2 are hydrogen;
- 5 - R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, $-NR_{11}R_{12}$, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-CONR_{11}R_{12}$, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy; preferably are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy; more preferably are independently selected from hydrogen, halogen, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy; and still more preferably R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy and $-SO_2-NH_2$;
- 10 - R_8 is selected from $-OH$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-C(O)C_{3-6}$ cycloalkyl C_{0-2} alkyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; preferably selected from $-OH$, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, preferably selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-5} acyl; more preferably R_8 is selected from $-OH$, C_{1-4} alkyl, C_{3-6} cycloalkyl C_{1-4} alkyl, C_{2-5} acyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, preferably said heterocycle is piperazinyl or morpholinyl, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-3} acyl;
- 15 - R_9 is selected from hydrogen and C_{1-4} alkyl, preferably is selected from methyl and hydrogen, more preferably is hydrogen; and
- 20 - R_{10} is selected from hydrogen and C_{1-4} alkyl, preferably is selected from methyl and hydrogen, more preferably is hydrogen; and
- 25 - R_{11} and R_{12} are independently selected from hydrogen and C_{1-4} alkyl, preferably from hydrogen and methyl, and more preferably R_{11} and R_{12} are hydrogen;
- 30 - R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, preferably from hydrogen and methyl, and more preferably R_{13} and R_{14} are hydrogen;
- 35 - R_{15} is selected from hydrogen and C_{1-4} alkyl, preferably from hydrogen and methyl, and more preferably R_{15} is hydrogen;

- n is 1, 2 or 3, preferably is 1 or 2, and each R₁₀ is independently selected from -OH, halogen, C₁₋₆alkyl, C₁₋₄alkoxyC₀₋₆alkyl, -SR₁₁ and -NR₁₁R₁₂; or two R₁₀ attached to a common carbon atom form an oxo; or two R₁₀ attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, more preferably a 3- to 5-membered cycloalkyl, and still more preferably a 3-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and halogen; more preferably, each R₁₀ is independently selected from halogen, C₁₋₄alkyl and -NR₁₁R₁₂, or two R₁₀ attached to a common carbon atom form an oxo; or two R₁₀ attached to adjacent carbon atoms are connected to form a 3- to 5-membered cycloalkyl, preferably a 3-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and halogen; and still more preferably, each R₁₀ is independently selected from chloro, fluoro, methyl, ethyl, and -NH₂, or two R₁₀ attached to a common carbon atom form an oxo; or two R₁₀ attached to adjacent carbon atoms are connected to form a 3-membered cycloalkyl;

and wherein:

- preferably at least one of R₃ to R₇ is not hydrogen and at least two of R₃ to R₇ are hydrogen;
- each R₁₁ and R₁₂ are independently selected from hydrogen and C₁₋₄alkyl, and preferably are selected from hydrogen and methyl; and
- R₁₅ is selected from hydrogen, C₁₋₆alkyl, haloC₁₋₆alkyl, -CN, -CONR₁₁R₁₂, -SO₂-R₁₁, -SO-R₁₁ and -SO₂-NR₁₁R₁₂; preferably is selected from hydrogen, -CN and C₁₋₄alkyl; and more preferably R₁₅ is selected from hydrogen and C₁₋₄alkyl;
- or a pharmaceutically acceptable salt or solvate thereof.

In another preferred embodiment, the invention relates to the compounds of formula (I) wherein:

- R₁ and R₂ are independently selected from hydrogen and C₁₋₄alkyl; preferably from hydrogen and methyl, and more preferably R₁ and R₂ are hydrogen;
- R₅ is selected from -OH, halogen, C₁₋₆alkyl, C₃₋₆cycloalkylC₀₋₄alkyl, -NR₁₁R₁₂, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₄alkoxyC₀₋₆alkyl, C₁₋₄alkoxyC₁₋₄alkoxy, -CONR₁₁R₁₂, -SO₂-NR₁₁R₁₂ and haloC₁₋₄alkoxy; preferably is selected from -OH, halogen, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₄alkoxyC₀₋₆alkyl, C₁₋₄alkoxyC₁₋₄alkoxy, -SO₂-NR₁₁R₁₂ and haloC₁₋₄alkoxy; more preferably is selected from halogen, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, -SO₂-NR₁₁R₁₂ and haloC₁₋₄alkoxy; still more

preferably is selected from fluoro, chloro, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy and $-\text{SO}_2-\text{NH}_2$; and still more preferably R_5 is fluoro;

- 5 - R_3 is selected from hydrogen, halogen and C_{1-6} alkyl; more preferably R_3 is selected from hydrogen, halogen and C_{1-4} alkyl, still more preferably R_3 is selected from hydrogen, fluoro, chloro, ethyl and methyl; and still more preferably R_3 is hydrogen;
- R_4 , R_6 and R_7 are hydrogen;
- 10 - R_8 is selected from $-\text{OH}$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-\text{C}(\text{O})\text{C}_{3-6}$ cycloalkyl C_{0-2} alkyl, $-\text{CONR}_{13}\text{R}_{14}$ and $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; preferably selected from $-\text{OH}$, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-\text{CONR}_{13}\text{R}_{14}$ and $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-
- 15 membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, preferably selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-5} acyl; more preferably R_8 is selected from $-\text{OH}$, C_{1-4} alkyl, C_{3-6} cycloalkyl C_{1-4} alkyl, C_{2-5} acyl, $-\text{CONR}_{13}\text{R}_{14}$ and
- 20 $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, preferably said heterocycle is piperazinyl or morpholinyl, said heterocycle can be optionally substituted by one
- 25 or more substituents independently selected from C_{1-4} alkyl and C_{2-3} acyl;
- R_9 is selected from hydrogen and C_{1-4} alkyl, preferably is selected from methyl and hydrogen, more preferably is hydrogen; and
- n is 1, 2 or 3, preferably is 1 or 2, and each R_{10} is independently selected from $-\text{OH}$, halogen, C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, $-\text{SR}_{11}$ and $-\text{NR}_{11}\text{R}_{12}$; or two R_{10}
- 30 attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, more preferably a 3- to 5-membered cycloalkyl, and still more preferably a 3-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and halogen; more
- 35 preferably, each R_{10} is independently selected from halogen, C_{1-4} alkyl and

5 $-\text{NR}_{11}\text{R}_{12}$, or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 5-membered cycloalkyl, preferably a 3-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and halogen; and still more preferably, each R_{10} is independently selected from chloro, fluoro, methyl, ethyl, and $-\text{NH}_2$, or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3-membered cycloalkyl;

and wherein:

- 10 each R_{11} and R_{12} are independently selected from hydrogen and C_{1-4} alkyl, and preferably are selected from hydrogen and methyl; and
 R_{15} is selected from hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, $-\text{CN}$, $-\text{CONR}_{11}\text{R}_{12}$, $-\text{SO}_2-\text{R}_{11}$, $-\text{SO}-\text{R}_{11}$ and $-\text{SO}_2-\text{NR}_{11}\text{R}_{12}$; preferably is selected from hydrogen, $-\text{CN}$ and C_{1-4} alkyl; and more preferably R_{15} is selected from hydrogen and C_{1-4} alkyl;
 15 or a pharmaceutically acceptable salt or solvate thereof.

In another preferred embodiment, the invention relates to the compounds of formula (I) wherein:

- R_1 and R_2 are independently selected from hydrogen and C_{1-4} alkyl; preferably from hydrogen and methyl, and more preferably R_1 and R_2 are hydrogen;
- 20 - R_4 and R_6 are independently selected from $-\text{OH}$, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, $-\text{NR}_{11}\text{R}_{12}$, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-\text{CONR}_{11}\text{R}_{12}$, $-\text{SO}_2-\text{NR}_{11}\text{R}_{12}$ and halo C_{1-4} alkoxy; preferably are selected from $-\text{OH}$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl and halo C_{1-4} alkoxy; more preferably are selected from halogen, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy and halo C_{1-4} alkoxy; and still more preferably are selected from fluoro, chloro, methyl, ethyl, methoxy, ethoxy, trifluoromethyl and trifluoromethoxy;
- R_3 , R_5 and R_7 are hydrogen;
- 25 - R_8 is selected from $-\text{OH}$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-\text{C}(\text{O})\text{C}_{3-6}$ cycloalkyl C_{0-2} alkyl, $-\text{CONR}_{13}\text{R}_{14}$ and $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; preferably selected from $-\text{OH}$, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl $-\text{CONR}_{13}\text{R}_{14}$ and $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-

- membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, preferably selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and C₂₋₅acyl; more preferably R₈ is selected from –OH, C₁₋₄alkyl, C₃₋₆cycloalkylC₁₋₄alkyl, C₂₋₅acyl, –CONR₁₃R₁₄ and –C(NR₁₅)NR₁₁R₁₂; wherein each R₁₃ and R₁₄ are independently selected from hydrogen and C₁₋₄alkyl, or R₁₃ and R₁₄ form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, preferably said heterocycle is piperazinyl or morpholinyl, said heterocycle can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and C₂₋₃acyl;
- R₉ is selected from hydrogen and C₁₋₄alkyl, preferably is selected from methyl and hydrogen, more preferably is hydrogen; and
 - n is 1, 2 or 3, preferably is 1 or 2, and each R₁₀ is independently selected from –OH, halogen, C₁₋₆alkyl, C₁₋₄alkoxyC₀₋₆alkyl, –SR₁₁ and –NR₁₁R₁₂; or two R₁₀ attached to a common carbon atom form an oxo; or two R₁₀ attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, more preferably a 3- to 5-membered cycloalkyl, and still more preferably a 3-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and halogen; more preferably, each R₁₀ is independently selected from halogen, C₁₋₄alkyl and –NR₁₁R₁₂, or two R₁₀ attached to a common carbon atom form an oxo; or two R₁₀ attached to adjacent carbon atoms are connected to form a 3- to 5-membered cycloalkyl, preferably a 3-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and halogen; and still more preferably, each R₁₀ is independently selected from chloro, fluoro, methyl, ethyl, and –NH₂, or two R₁₀ attached to a common carbon atom form an oxo; or two R₁₀ attached to adjacent carbon atoms are connected to form a 3-membered cycloalkyl;
- and wherein:
- each R₁₁ and R₁₂ are independently selected from hydrogen and C₁₋₄alkyl, or preferably are selected from hydrogen and methyl; and
- R₁₅ is selected from hydrogen, C₁₋₆alkyl, haloC₁₋₆alkyl, –CN, –CONR₁₁R₁₂, –SO₂–R₁₁, –SO–R₁₁ and –SO₂–NR₁₁R₁₂; preferably is selected from hydrogen, –CN and C₁₋₄alkyl;
- and more preferably R₁₅ is selected from hydrogen and C₁₋₄alkyl;

or a pharmaceutically acceptable salt or solvate thereof.

In another preferred embodiment, the invention relates to the compounds of formula (I) wherein:

- R_1 and R_2 are independently selected from hydrogen and C_{1-4} alkyl; preferably from hydrogen and methyl, and more preferably R_1 and R_2 are hydrogen;
- two of R_3 to R_7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl; and preferably the other three of R_3 to R_7 are hydrogen; more preferably, R_4 and R_5 are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl, and preferably R_3 , R_6 and R_7 are hydrogen; still more preferably R_4 and R_5 are connected to form a saturated 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O atoms, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl, and R_3 , R_6 and R_7 are hydrogen; and still more preferably R_4 and R_5 are connected to form a 1,4-dioxane, and R_3 , R_6 and R_7 are hydrogen;
- R_8 is selected from $-OH$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-C(O)C_{3-6}$ cycloalkyl C_{0-2} alkyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; preferably selected from $-OH$, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, preferably selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-5} acyl; more preferably R_8 is selected from $-OH$, C_{1-4} alkyl, C_{3-6} cycloalkyl C_{1-4} alkyl, C_{2-5} acyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, preferably said heterocycle is piperazinyl or morpholinyl, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-3} acyl;

- R_9 is selected from hydrogen and C_{1-4} alkyl, preferably is selected from methyl and hydrogen, more preferably is hydrogen; and
- n is 1, 2 or 3, preferably is 1 or 2, and each R_{10} is independently selected from $-OH$, halogen, C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, $-SR_{11}$ and $-NR_{11}R_{12}$; or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, more preferably a 3- to 5-membered cycloalkyl, and still more preferably a 3-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and halogen; more preferably, each R_{10} is independently selected from halogen, C_{1-4} alkyl and $-NR_{11}R_{12}$, or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 5-membered cycloalkyl, preferably a 3-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and halogen; and still more preferably, each R_{10} is independently selected from chloro, fluoro, methyl, ethyl, and $-NH_2$, or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3-membered cycloalkyl;

and wherein:

- each R_{11} and R_{12} are independently selected from hydrogen and C_{1-4} alkyl, or preferably are selected from hydrogen and methyl; and
- R_{15} is selected from hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, $-CN$, $-CONR_{11}R_{12}$, $-SO_2-R_{11}$, $-SO-R_{11}$ and $-SO_2-NR_{11}R_{12}$; preferably is selected from hydrogen, $-CN$ and C_{1-4} alkyl; and more preferably R_{15} is selected from hydrogen and C_{1-4} alkyl;
- or a pharmaceutically acceptable salt or solvate thereof.

In a preferred embodiment, the invention relates to the compounds of formula (I) wherein:

- R_1 and R_2 are independently selected from hydrogen and C_{1-4} alkyl; preferably from hydrogen and methyl, and more preferably R_1 and R_2 are hydrogen;
- R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, $-NR_{11}R_{12}$, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-CONR_{11}R_{12}$, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy; preferably are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy; more preferably are independently selected from hydrogen,

halogen, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, -SO₂-NR₁₁R₁₂ and haloC₁₋₄alkoxy; and still more preferably R₃, R₄, R₅, R₆ and R₇ are independently selected from hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy and -SO₂-NH₂;

- 5 - R₈ is selected from -OH, C₁₋₆alkyl, haloC₁₋₆alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₀₋₄alkyl, C₃₋₆cycloalkylC₀₋₄alkyl, C₂₋₅acyl, -C(O)C₃₋₆cycloalkylC₀₋₂alkyl, -CONR₁₃R₁₄ and -C(NR₁₅)NR₁₁R₁₂; preferably selected from -OH, C₁₋₆alkyl, C₃₋₆cycloalkylC₀₋₄alkyl, C₂₋₅acyl, -CONR₁₃R₁₄ and -C(NR₁₅)NR₁₁R₁₂; wherein each R₁₃ and R₁₄ are independently selected from hydrogen and C₁₋₄alkyl, or R₁₃ and R₁₄ form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, preferably selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and C₂₋₅acyl; more preferably R₈ is selected from -OH, C₁₋₄alkyl, C₃₋₆cycloalkylC₁₋₄alkyl, C₂₋₅acyl, -CONR₁₃R₁₄ and -C(NR₁₅)NR₁₁R₁₂; wherein each R₁₃ and R₁₄ are independently selected from hydrogen and C₁₋₄alkyl, or R₁₃ and R₁₄ form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, preferably said heterocycle is piperazinyl or morpholinyl, said heterocycle can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and C₂₋₃acyl;
- 10 - R₉ is selected from hydrogen and C₁₋₄alkyl, preferably is selected from methyl and hydrogen, more preferably is hydrogen; and
- 15 - n is 0;

25 and wherein:

preferably at least one of R₃ to R₇ is not hydrogen and at least two of R₃ to R₇ are hydrogen;

each R₁₁ and R₁₂ are independently selected from hydrogen and C₁₋₄alkyl, and preferably are selected from hydrogen and methyl; and

- 30 R₁₅ is selected from hydrogen, C₁₋₆alkyl, haloC₁₋₆alkyl, -CN, -CONR₁₁R₁₂, -SO₂-R₁₁, -SO-R₁₁ and -SO₂-NR₁₁R₁₂; preferably is selected from hydrogen, -CN and C₁₋₄alkyl; and more preferably R₁₅ is selected from hydrogen and C₁₋₄alkyl; or a pharmaceutically acceptable salt or solvate thereof.

35 In another preferred embodiment, the invention relates to the compounds of formula (I) wherein:

- R_1 and R_2 are independently selected from hydrogen and C_{1-4} alkyl; preferably from hydrogen and methyl, and more preferably R_1 and R_2 are hydrogen;
- R_5 is selected from $-OH$, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, $-NR_{11}R_{12}$, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-CONR_{11}R_{12}$, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy; preferably is selected from $-OH$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy; more preferably is selected from halogen, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy; still more preferably is selected from fluoro, chloro, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy and $-SO_2-NH_2$; and still more preferably R_5 is fluoro;
- R_3 is selected from hydrogen, halogen and C_{1-6} alkyl; more preferably R_3 is selected from hydrogen, halogen and C_{1-4} alkyl, still more preferably R_3 is selected from hydrogen, fluoro, chloro, ethyl and methyl; and still more preferably R_3 is hydrogen;
- R_4 , R_6 and R_7 are hydrogen;
- R_8 is selected from $-OH$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-C(O)C_{3-6}$ cycloalkyl C_{0-2} alkyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; preferably selected from $-OH$, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, preferably selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-5} acyl; more preferably R_8 is selected from $-OH$, C_{1-4} alkyl, C_{3-6} cycloalkyl C_{1-4} alkyl, C_{2-5} acyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, preferably said heterocycle is piperazinyl or morpholinyl, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-3} acyl;

- R₉ is selected from hydrogen and C₁₋₄alkyl, preferably is selected from methyl and hydrogen, more preferably is hydrogen; and
- n is 0;

and wherein:

- 5 each R₁₁ and R₁₂ are independently selected from hydrogen and C₁₋₄alkyl, and preferably are selected from hydrogen and methyl; and
- R₁₅ is selected from hydrogen, C₁₋₆alkyl, haloC₁₋₆alkyl, -CN, -CONR₁₁R₁₂, -SO₂-R₁₁, -SO-R₁₁ and -SO₂-NR₁₁R₁₂; preferably is selected from hydrogen, -CN and C₁₋₄alkyl; and more preferably R₁₅ is selected from hydrogen and C₁₋₄alkyl;
- 10 or a pharmaceutically acceptable salt or solvate thereof.

In another preferred embodiment, the invention relates to the compounds of formula (I) wherein:

- R₁ and R₂ are independently selected from hydrogen and C₁₋₄alkyl; preferably from hydrogen and methyl, and more preferably R₁ and R₂ are hydrogen;
 - 15 - R₄ and R₆ are independently selected from -OH, halogen, C₁₋₆alkyl, C₃₋₆cycloalkylC₀₋₄alkyl, -NR₁₁R₁₂, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₄alkoxyC₀₋₆alkyl, C₁₋₄alkoxyC₁₋₄alkoxy, -CONR₁₁R₁₂, -SO₂-NR₁₁R₁₂ and haloC₁₋₄alkoxy; preferably are selected from -OH, halogen, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₄alkoxyC₀₋₆alkyl and haloC₁₋₄alkoxy; preferably are selected from halogen, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy and haloC₁₋₄alkoxy; more preferably are selected from fluoro, chloro, methyl, ethyl, methoxy, ethoxy, trifluoromethyl and trifluoromethoxy;
 - R₃, R₅ and R₇ are hydrogen;
 - R₈ is selected from -OH, C₁₋₆alkyl, haloC₁₋₆alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₀₋₄alkyl, C₃₋₆cycloalkylC₀₋₄alkyl, C₂₋₅acyl, -C(O)C₃₋₆cycloalkylC₀₋₂alkyl, -CONR₁₃R₁₄ and -C(NR₁₅)NR₁₁R₁₂; preferably selected from -OH, C₁₋₆alkyl, C₃₋₆cycloalkylC₀₋₄alkyl, C₂₋₅acyl, -CONR₁₃R₁₄ and -C(NR₁₅)NR₁₁R₁₂; wherein each R₁₃ and R₁₄ are independently selected from hydrogen and C₁₋₄alkyl, or R₁₃ and R₁₄ form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, preferably selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and C₂₋₅acyl; more preferably R₈ is selected from -OH, C₁₋₄alkyl, C₃₋₆cycloalkylC₁₋₄alkyl, C₂₋₅acyl, -CONR₁₃R₁₄ and
- 25
- 30

- $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, preferably said heterocycle is piperazinyl or morpholinyl, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-3} acyl;
- R_9 is selected from hydrogen and C_{1-4} alkyl, preferably is selected from methyl and hydrogen, more preferably is hydrogen; and
 - n is 0;
- and wherein:
- each R_{11} and R_{12} are independently selected from hydrogen and C_{1-4} alkyl, and preferably are selected from hydrogen and methyl; and
- R_{15} is selected from hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, $-\text{CN}$, $-\text{CONR}_{11}\text{R}_{12}$, $-\text{SO}_2-\text{R}_{11}$, $-\text{SO}-\text{R}_{11}$ and $-\text{SO}_2-\text{NR}_{11}\text{R}_{12}$; preferably is selected from hydrogen, $-\text{CN}$ and C_{1-4} alkyl; and more preferably R_{15} is selected from hydrogen and C_{1-4} alkyl;
- or a pharmaceutically acceptable salt or solvate thereof.

In another preferred embodiment, the invention relates to the compounds of formula (I) wherein:

- R_1 and R_2 are independently selected from hydrogen and C_{1-4} alkyl; preferably from hydrogen and methyl, and more preferably R_1 and R_2 are hydrogen;
- two of R_3 to R_7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl; and preferably the other three of R_3 to R_7 are hydrogen; more preferably, R_4 and R_5 are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl, and preferably R_3 , R_6 and R_7 are hydrogen; still more preferably R_4 and R_5 are connected to form a saturated 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O atoms, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl, and R_3 , R_6 and R_7 are hydrogen; and still more preferably R_4 and R_5 are connected to form a 1,4-dioxane, and R_3 , R_6 and R_7 are hydrogen;
- R_8 is selected from $-\text{OH}$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-\text{C}(\text{O})\text{C}_{3-6}$ cycloalkyl C_{0-2} alkyl,

- 5 $-\text{CONR}_{13}\text{R}_{14}$ and $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; preferably selected from $-\text{OH}$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{0-4}\text{alkyl}$, $\text{C}_{2-5}\text{acyl}$, $-\text{CONR}_{13}\text{R}_{14}$ and $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and $\text{C}_{1-4}\text{alkyl}$, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-
 10 membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, preferably selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from $\text{C}_{1-4}\text{alkyl}$ and $\text{C}_{2-5}\text{acyl}$; more preferably R_8 is selected from $-\text{OH}$, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{2-5}\text{acyl}$, $-\text{CONR}_{13}\text{R}_{14}$ and
 15 $-\text{C}(\text{NR}_{15})\text{NR}_{11}\text{R}_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and $\text{C}_{1-4}\text{alkyl}$, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, preferably said heterocycle is piperazinyl or morpholinyl, said heterocycle can be optionally substituted by one or more substituents independently selected from $\text{C}_{1-4}\text{alkyl}$ and $\text{C}_{2-3}\text{acyl}$;
 - R_9 is selected from hydrogen and $\text{C}_{1-4}\text{alkyl}$, preferably is selected from methyl and hydrogen, more preferably is hydrogen; and
 - n is 0;

and wherein:

- 20 each R_{11} and R_{12} are independently selected from hydrogen and $\text{C}_{1-4}\text{alkyl}$, and preferably are selected from hydrogen and methyl; and
 R_{15} is selected from hydrogen, $\text{C}_{1-6}\text{alkyl}$, $\text{haloC}_{1-6}\text{alkyl}$, $-\text{CN}$, $-\text{CONR}_{11}\text{R}_{12}$, $-\text{SO}_2-\text{R}_{11}$, $-\text{SO}-\text{R}_{11}$ and $-\text{SO}_2-\text{NR}_{11}\text{R}_{12}$; preferably is selected from hydrogen, $-\text{CN}$ and $\text{C}_{1-4}\text{alkyl}$; and more preferably R_{15} is selected from hydrogen and $\text{C}_{1-4}\text{alkyl}$;
 25 or a pharmaceutically acceptable salt or solvate thereof.

In another preferred embodiment, compound of formula (I) is selected from the following list of compounds:

- 30 - N'-(4-fluorophenyl)-1,5-dimethylpyrrolidine-2-carbohydrazide
 - (*R*)-2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
 - (*S*)-2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
 - 2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
 - 2-(2-(4-fluoro-2-methylphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
 - 2-(2-(3,5-difluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
 - 2-(2-(4-(trifluoromethoxy)phenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide

- 2-(2-(4-(trifluoromethyl)phenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-chloro-2-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-methoxyphenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 2-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)hydrazinecarbonyl)pyrrolidine-1-
- 5 carboxamide
- 2-(2-(4-sulfamoylphenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- (2*S*,4*S*)-4-fluoro-2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-
- carboxamide
- (*R*)-1-acetyl-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide
- 10 – N'-(4-fluorophenyl)-1-hydroxypyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-1,2-dimethylpyrrolidine-2-carbohydrazide
- 2-(2-(4-fluorophenyl)hydrazinecarbonyl)-N,N-dimethylpyrrolidine-1-carboxamide
- N'-(4-fluorophenyl)-1-(piperazine-1-carbonyl)pyrrolidine-2-carbohydrazide
- 1-(4-acetylpiperazine-1-carbonyl)-N'-(4-fluorophenyl)pyrrolidine-2-
- 15 carbohydrazide
- N'-(4-fluorophenyl)-1-(morpholine-4-carbonyl)pyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-1-methyl-5-oxopyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide
- 4-amino-N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide
- 20 – 4-fluoro-N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide
- (S)-1-(cyclopropylmethyl)-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-3-methyl-3-azabicyclo[3.1.0]hexane-2-carbohydrazide
- N'-(4-fluorophenyl)-1,4-dimethylpyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-1,3-dimethylpyrrolidine-2-carbohydrazide
- 25 – 1-ethyl-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide
- 2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboximidamide
- 2-(2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(1-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 30 – 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(3-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(2-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-chlorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(3-chlorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide

- 2-(2-(2-chlorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(3-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(2-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 5 – 2-(2-(p-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(m-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(o-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(3-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 10 – 2-(2-(2-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- ethyl 4-(2-(carbamoylpropyl)hydrazinyl)benzoate
- ethyl 3-(2-(carbamoylpropyl)hydrazinyl)benzoate
- ethyl 2-(2-(carbamoylpropyl)hydrazinyl)benzoate
- 2-(2-(4-cyanophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 15 – 2-(2-(3-cyanophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(2-cyanophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 4-(2-(carbamoylpropyl)hydrazinyl)benzoic acid
- 3-(2-(carbamoylpropyl)hydrazinyl)benzoic acid
- 2-(2-(carbamoylpropyl)hydrazinyl)benzoic acid
- 20 – N-methyl-2-(2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-methyl-2-(1-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-methyl-2-(2-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- 2-(2-(3-fluorophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- 25 – 2-(2-(2-fluorophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- 2-(2-(4-chlorophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- 2-(2-(3-chlorophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- 2-(2-(2-chlorophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-
- 30 carboxamide
- 2-(2-(3-methoxyphenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-
- carboxamide
- 2-(2-(2-methoxyphenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-
- carboxamide

- N-methyl-2-(2-(p-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-methyl-2-(2-(m-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-methyl-2-(2-(o-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-methyl-2-(2-(4-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-
- 5 carboxamide
- N-methyl-2-(2-(3-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-
- carboxamide
- N-methyl-2-(2-(2-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-
- carboxamide
- 10 – ethyl 4-(2-((methylcarbamoyl)prolyl)hydrazinyl)benzoate
- ethyl 3-(2-((methylcarbamoyl)prolyl)hydrazinyl)benzoate
- ethyl 2-(2-((methylcarbamoyl)prolyl)hydrazinyl)benzoate
- 2-(2-(4-cyanophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- 2-(2-(3-cyanophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- 15 – 2-(2-(2-cyanophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- 4-(2-((methylcarbamoyl)prolyl)hydrazinyl)benzoic acid
- 3-(2-((methylcarbamoyl)prolyl)hydrazinyl)benzoic acid
- 2-(2-((methylcarbamoyl)prolyl)hydrazinyl)benzoic acid
- N-cyclopropyl-2-(2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 20 – N-cyclopropyl-2-(1-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-
- carboxamide
- N-cyclopropyl-2-(2-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-
- carboxamide
- N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-
- 25 carboxamide
- N-cyclopropyl-2-(2-(3-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-
- carboxamide
- N-cyclopropyl-2-(2-(2-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-
- carboxamide
- 30 – 2-(2-(4-chlorophenyl)hydrazine-1-carbonyl)-N-cyclopropylpyrrolidine-1-
- carboxamide
- 2-(2-(3-chlorophenyl)hydrazine-1-carbonyl)-N-cyclopropylpyrrolidine-1-
- carboxamide

- 2-(2-(2-chlorophenyl)hydrazine-1-carbonyl)-N-cyclopropylpyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 5 – N-cyclopropyl-2-(2-(3-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(2-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(p-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 10 – N-cyclopropyl-2-(2-(m-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(o-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(4-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(3-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 15 – N-cyclopropyl-2-(2-(2-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- ethyl 4-(2-((cyclopropylcarbamoyl)prolyl)hydrazinyl)benzoate
- ethyl 3-(2-((cyclopropylcarbamoyl)prolyl)hydrazinyl)benzoate
- 20 – ethyl 2-(2-((cyclopropylcarbamoyl)prolyl)hydrazinyl)benzoate
- 2-(2-(4-cyanophenyl)hydrazine-1-carbonyl)-N-cyclopropylpyrrolidine-1-carboxamide
- 2-(2-(3-cyanophenyl)hydrazine-1-carbonyl)-N-cyclopropylpyrrolidine-1-carboxamide
- 25 – 2-(2-(2-cyanophenyl)hydrazine-1-carbonyl)-N-cyclopropylpyrrolidine-1-carboxamide
- 4-(2-((cyclopropylcarbamoyl)prolyl)hydrazinyl)benzoic acid
- 3-(2-((cyclopropylcarbamoyl)prolyl)hydrazinyl)benzoic acid
- 2-(2-((cyclopropylcarbamoyl)prolyl)hydrazinyl)benzoic acid
- 30 – ethyl (2-(2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(1-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate

- ethyl (2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(3-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- 5 – ethyl (2-(2-(2-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(4-chlorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(3-chlorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- 10 – ethyl (2-(2-(2-chlorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- 15 – ethyl (2-(2-(3-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(2-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(p-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- 20 – ethyl (2-(2-(m-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(o-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(4-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(3-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- 25 – ethyl (2-(2-(2-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl 4-(2-(((1-ethoxy-1-oxopropan-2-yl)carbamoyl)prolyl)hydrazinyl)benzoate
- ethyl 3-(2-(((1-ethoxy-1-oxopropan-2-yl)carbamoyl)prolyl)hydrazinyl)benzoate
- 30 – ethyl 2-(2-(((1-ethoxy-1-oxopropan-2-yl)carbamoyl)prolyl)hydrazinyl)benzoate
- ethyl (2-(2-(4-cyanophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- ethyl (2-(2-(3-cyanophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate

- ethyl (2-(2-(2-cyanophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carbonyl)alaninate
- 4-(2-(((1-ethoxy-1-oxopropan-2-yl)carbamoyl)propyl)hydrazinyl)benzoic acid
- 3-(2-(((1-ethoxy-1-oxopropan-2-yl)carbamoyl)propyl)hydrazinyl)benzoic acid
- 5 – 2-(2-(((1-ethoxy-1-oxopropan-2-yl)carbamoyl)propyl)hydrazinyl)benzoic acid
- methyl 2-(2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(1-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- 10 – methyl 2-(2-(3-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(2-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(4-chlorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(3-chlorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(2-chlorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- 15 – methyl 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(3-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(2-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(p-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(m-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- 20 – methyl 2-(2-(o-tolyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(4-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(3-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- 25 – methyl 2-(2-(2-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(4-(ethoxycarbonyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(3-(ethoxycarbonyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- 30 – methyl 2-(2-(2-(ethoxycarbonyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(4-cyanophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- methyl 2-(2-(3-cyanophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate

- methyl 2-(2-(2-cyanophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- 4-(2-((methoxycarbonyl)prolyl)hydrazinyl)benzoic acid
- 3-(2-((methoxycarbonyl)prolyl)hydrazinyl)benzoic acid
- 2-(2-((methoxycarbonyl)prolyl)hydrazinyl)benzoic acid
- 5 – 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- N-ethyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N-isopropylpyrrolidine-1-carboxamide
- 10 – 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N-(2-hydroxyethyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N-(2-methoxyethyl)pyrrolidine-1-carboxamide
- N-(2-aminoethyl)-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 15 – N-(2-(dimethylamino)ethyl)-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N-(2-(piperazin-1-yl)ethyl)pyrrolidine-1-carboxamide
- 20 – 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N-(2-morpholinoethyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 25 – N-cyclobutyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclopentyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 30 – 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-N,N-dimethylpyrrolidine-1-carboxamide
- N'-(4-fluorophenyl)-1-(piperazine-1-carbonyl)pyrrolidine-2-carbohydrazide

- N'-(4-fluorophenyl)-1-(4-methylpiperazine-1-carbonyl)pyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-1-(morpholine-4-carbonyl)pyrrolidine-2-carbohydrazide
- N-(2-amino-2-oxoethyl)-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 5 – N-(1-amino-1-oxopropan-2-yl)-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 10 – N-(1-amino-3-methoxy-1-oxobutan-2-yl)-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 4-amino-3-(2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamido)-4-oxobutan-2-yl acetate
- N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 15 – methyl 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- ethyl 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- isopropyl 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- cyclopentyl 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- 20 – 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-N-methylpyrrolidine-1-carboxamide
- N-ethyl-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-isopropyl-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 25 – N-(2-hydroxyethyl)-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-(2-methoxyethyl)-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 30 – N-(2-aminoethyl)-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-(2-(dimethylamino)ethyl)-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide

- 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-N-(2-(piperazin-1-yl)ethyl)pyrrolidine-1-carboxamide
- 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-N-(2-(4-methylpiperazin-1-yl)ethyl)pyrrolidine-1-carboxamide
- 5 – 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-N-(2-morpholinoethyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclobutyl-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 10 – N-cyclopentyl-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolidine-1-carboxamide
- 15 – 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-N,N-dimethylpyrrolidine-1-carboxamide
- N'-(4-methoxyphenyl)-1-(piperazine-1-carbonyl)pyrrolidine-2-carbohydrazide
- N'-(4-methoxyphenyl)-1-(4-methylpiperazine-1-carbonyl)pyrrolidine-2-carbohydrazide
- 20 – N'-(4-methoxyphenyl)-1-(morpholine-4-carbonyl)pyrrolidine-2-carbohydrazide
- N-(2-amino-2-oxoethyl)-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-(1-amino-1-oxopropan-2-yl)-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 25 – N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-(1-amino-3-methoxy-1-oxobutan-2-yl)-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 4-amino-3-(2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamido)-4-oxobutan-2-yl acetate
- 30 – N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- methyl 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- ethyl 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate

- isopropyl 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- cyclopentyl 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 5 – 5-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-2,2-dimethylpyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-methylpyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-isopropylpyrrolidine-1-carboxamide
- 10 – 6-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-5-azaspiro[2.4]heptane-5-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-methoxypyrrolidine-1-carboxamide
- 1-carbamoyl-5-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidin-3-yl acetate
- 15 – 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-fluoropyrrolidine-1-carboxamide
- 4,4-difluoro-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-(trifluoromethyl)pyrrolidine-1-carboxamide
- 20 – 4-cyano-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-3-phenylpyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-3-hydroxypyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-3-methoxypyrrolidine-1-carboxamide
- 1-carbamoyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidin-3-yl acetate
- 25 – 2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-3-azabicyclo[3.1.0]hexane-3-carboxamide
- 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 5-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-2,2-dimethylpyrrolidine-1-carboxamide
- 30 – 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-4-methylpyrrolidine-1-carboxamide
- 4-isopropyl-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide

- 6-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-5-azaspiro[2.4]heptane-5-carboxamide
- 4-hydroxy-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 5 – 4-methoxy-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 1-carbamoyl-5-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidin-3-yl acetate
- 4-fluoro-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 10 – 4,4-difluoro-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-4-(trifluoromethyl)pyrrolidine-1-carboxamide
- 4-cyano-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 15 – 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-3-phenylpyrrolidine-1-carboxamide
- 3-hydroxy-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 20 – 3-methoxy-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 1-carbamoyl-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidin-3-yl acetate
- 2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)-3-azabicyclo[3.1.0]hexane-3-carboxamide
- 25 – N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-5-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-2,2-dimethylpyrrolidine-1-carboxamide
- 30 – N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-methylpyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-isopropylpyrrolidine-1-carboxamide

- N-cyclopropyl-6-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-5-azaspiro[2.4]heptane-5-carboxamide
- N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxamide
- 5 – N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-methoxypyrrolidine-1-carboxamide
- 1-(cyclopropylcarbamoyl)-5-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidin-3-yl acetate
- N-cyclopropyl-4-fluoro-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 10 – N-cyclopropyl-4,4-difluoro-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-4-(trifluoromethyl)pyrrolidine-1-carboxamide
- 15 – 4-cyano-N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-3-phenylpyrrolidine-1-carboxamide
- N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-3-hydroxypyrrolidine-1-carboxamide
- 20 – N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-3-methoxypyrrolidine-1-carboxamide
- 1-(cyclopropylcarbamoyl)-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)pyrrolidin-3-yl acetate
- 25 – N-cyclopropyl-2-(2-(4-fluorophenyl)hydrazine-1-carbonyl)-3-azabicyclo[3.1.0]hexane-3-carboxamide
- N-cyclopropyl-2-(2-(4-methoxyphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide

and the pharmaceutically acceptable salts or solvates thereof.

30

In another embodiment, the invention relates to compounds of formula (I) having a minimal inhibitory concentration (MIC) against *Acinetobacter baumannii* of less than about 50 µg/mL, preferably of less than about 25 µg/mL, and more preferably of less than about 10 µg/mL, in an assay as the one described in Example 31.

In another embodiment, the invention relates to compounds of formula (I) having (a) a MIC against *Acinetobacter baumannii* of less than about 50 µg/mL, preferably of less than about 25 µg/mL, and more preferably of less than about 10 µg/mL; and (b) a MIC greater than about 100 µg/mL against at least one of the following bacteria: *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Enterococcus faecium*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae* and *Escherichia coli*, preferably against at least two of these bacteria, and still more preferably against at least three of these bacteria; in an assay as the one described in Example 31.

10 Use of the compounds

As shown in Example 31, surprisingly, the compounds of the present invention showed high antimicrobial activity against the bacteria *A. baumannii*, with minimal inhibitory concentration (MIC) values equal to or less than 25 µg/mL, or even lower, for all the assayed compounds, while they were inactive against the other bacteria tested, i.e. *Staphylococcus aureus* (*S. aureus*), *Streptococcus pneumoniae* (*S. pneumoniae*), *Enterococcus faecium* (*E. faecium*), *Pseudomonas aeruginosa* (*P. aeruginosa*), *Klebsiella pneumoniae* (*K. pneumoniae*) and *Escherichia coli* (*E. coli*), with MIC values greater than 128 for almost all the compounds.

Therefore, a second aspect of the present invention is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament.

A third aspect of the present invention is a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as antibacterial agent, preferably for treating or preventing *A. baumannii* infections.

A preferred embodiment relates to any of the particular and preferred embodiments of compounds formula (I) above disclosed in relation with the first aspect of the present invention for use as antibacterial agents, preferably for treating or preventing *A. baumannii* infections.

This aspect of the present invention can be similarly reformulated according to the following aspects.

Thus, another aspect of the present invention relates to a method for treating bacterial infections in a subject in need thereof, comprising administering an effective amount of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or solvate thereof, to the subject.

Another aspect of the present invention relates to the use of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or solvate thereof, as antibacterial agent.

Another aspect of the present invention relates to a method for treating a
5 *A. baumannii* infection in a subject in need thereof, comprising administering an effective amount of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or solvate thereof, to the subject.

Still another aspect of the present invention relates to the use of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or
10 solvate thereof, for treating *A. baumannii* infections.

The compounds of the present invention may be used without limitation for the treatment of all infections caused by *A. baumannii*. For example, they can be used for treating pneumonia, particularly ventilator-associated pneumonia; surgical site infections; wound infections; skin and soft tissue infections; urinary tract infections;
15 post-operative meningitis; any kind of catheter-related infection, for example catheter-associated urinary tract infection; or bloodstream infection.

As used herein the terms "treatment" or "treating" refer to both prophylactic treatment and therapeutic treatment of *A. baumannii* infections i.e. to preventing or inhibiting the infection from occurring in a subject that may be
20 predisposed to be infected but has not yet been diagnosed as having the infection, and to reducing or eliminating the infection after its onset in a subject, as well as to relieving and alleviating its associated symptoms.

Particularly, the terms "prevention" or "preventing" refer more specifically to prophylactic treatment of *A. baumannii* infections i.e. to preventing or inhibiting the
25 infection from occurring in a subject that may be predisposed to be infected but has not yet been diagnosed as having the infection.

As used herein the term "subject" is referred to human beings.

As used herein the term "in a subject in need thereof" relates to both a subject who has not been infected but that may be predisposed to acquire the infection
30 as well as to a subject who has been infected with *A. baumannii*.


The compounds of the present invention are administered in a dose which is therapeutically active for treating the infections, and the skilled in the art will have no difficulty for adjusting the exact dose to be administered based on the kind of patient, the specific infection to be treated and its severity.

Typically, the compounds of the invention are administered in an amount ranging from 1 to 20 mg/kg of body weight.

In another embodiment, due to the high activity of the compounds of formula (I) against *A. Baumannii*, these compounds can be used in therapy in combination with other antibacterials, typically with broad-spectrum antibacterials, which may have less activity or be not active specifically against *A. Baumannii*, to thus reinforce the antibacterial effectiveness of the therapy. The compounds of formula (I) may be combined with any kind of antibacterial agent used in therapy, for example, with β -lactam antibiotics, such as penicillins, cephalosporins, monobactams or carbapenems, among others.

The combination of the compound of formula (I) with an additional antibacterial agent may be performed by administering both substances as a fixed-dose combination in the form of a single pharmaceutical dosage form or, alternatively, both drugs can be administered independently, according to a therapeutic combination schedule.

Alternatively, the compound of formula (I) may be combined with another antibacterial agent by chemically bonding both compounds to form a single molecule. For example a compound of formula (I) may be attached to a carbapenem-type antibacterial compound, to form a dual compound, having, for example, the following formula:



Pharmaceutical compositions

A fourth aspect of the invention relates to a pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutical acceptable salt or solvate thereof and at least one pharmaceutically acceptable excipient and/or carrier.

The pharmaceutical composition that is an aspect of the present invention can be adapted to any form of administration, for example for oral, parenteral, by inhalation, rectal, transdermal or topical administration. Likewise, depending on the intended route, the composition may be in solid, liquid, or semi-solid form, and all of them are encompassed within the scope of the present invention.

The excipients suitable to be used in the pharmaceutical composition as well as their preparation methods will vary depending on the form and intended route of administration.

5 Solid compositions for oral use include, for example, tablets, capsules, and granulates. They may contain excipients such, for example, anticaking agents, binders, diluents, disintegrating agents, glidants, lubricants, flavoring agents and sweetening agents. Tablets can be coated with diverse coating agents. Capsules can be either hard capsules or soft capsules as are well known in the art.

10 Liquid forms for oral administration include emulsions, solutions, suspensions and syrups and can incorporate diverse pharmaceutically acceptable carriers or excipients, such as a liquid vehicle, emulsifying agents, suspending agents, flavoring agents, coloring agents, buffering agents, preservative agents, and diluents.

Injectable preparations comprise sterile solutions, suspensions or emulsions in aqueous or non-aqueous solvents such as propylene glycol, polyethylene glycol or vegetable oils, and can be administered intravenously, subcutaneously or intramuscularly.

Compositions for rectal administration can be in the form of suppositories, for example on an oily base. They may contain other excipients such adsorbents, surface-active agents, antioxidants, preservatives and colorants.

20 Compositions for topical administration can be in form of creams, gels, ointments or pastes, for example. They may contain excipients such emulsifiers, viscosity-increasing agents, preservatives, antioxidants, and stabilizing agents.

In each case, the pharmaceutical compositions can be prepared using standard methods that are well known to the skilled in the art such as those described
25 in handbooks of pharmaceutical technology, for example the book *Remington The Science and Practice of Pharmacy*, 20th edition, Lippincott, Williams & Wilkins, Philadelphia, 2000 [ISBN: 0-683-306472].


Also the excipients and/or carriers to be used in such compositions are well known, as disclosed for example, in the book R.C.Rowe, P.J.Sheskey and
30 M.E.Quinn, *Handbook of Pharmaceutical Excipients*, 6th edition, Pharmaceutical Press, London, 2009 [ISBN: 978 0 85369 792 3].

Such compositions typically contain from 1 to 40% by weight of compound of formula (I) as active ingredient, the remainder of the composition being pharmaceutical carriers and/or excipients.


Optionally, the pharmaceutical composition can contain an additional active ingredient, in combination with the compound of formula (I), preferably the pharmaceutical composition can contain another antibacterial agent.

5 Process for preparing the compounds of the invention

A fifth aspect of the present invention relates to a process for the preparation of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or solvate thereof, which comprises reacting a compound of formula (II)




10 with a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof:



wherein R₁₆ is hydrogen or a C₁₋₄alkyl, R₁₇ is hydrogen or R₈, and wherein n and R₁ to R₁₅, have the same meaning as defined above in relation to compounds of formula (I).

15 The process can be represented according to the Scheme I:



SCHEME I


20 As it is well known to the skilled in the art, the use of conventional protecting groups may be necessary to prevent undesired reactions of some reactive or labile groups. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protecting and deprotecting various functional groups

are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and G. M. Wuts, "*Protecting Groups in Organic Synthesis*", Third Edition, Wiley, New York, 1999, and the references cited therein.

5 For example, the process may involve the reaction of an amino-protected form of the compound of formula (II), or/and an amino-protected form of the compound of formula (III), and the process may be followed, if necessary, by the removal of any protective groups that may be present.

10 In one embodiment R_{17} is R_8 and the compound of formula II is a compound of formula (II_a). According to this embodiment, the compound of formula (I) can be directly obtained after the coupling reaction between the compound of formula (II_a) and the compound of formula (III), followed, if necessary, by the removal of any protective groups that may be present (Method-A).

15 In another embodiment R_{17} is hydrogen and the compound of formula (II) is a compound of formula (II_b). According to this embodiment, the compound of formula (II_b), optionally in protected form, is first coupled with the compound of formula (III), to form a compound of formula (IV), and the group R_8 can be introduced after the coupling reaction (Method-B), as represented below in Scheme II.



20

SCHEME II

To protect the amine group of the pyrrolidine ring, as well as any other amine group which may need to be protected, any suitable protecting group may be used, for example, the *tert*-butoxycarbonyl protecting group (Boc) or the carboxybenzyl protecting group (Cbz, or Z) may be used.

25

In another embodiment, the compound of formula (I) obtained according to the process of Scheme I can be converted into another compound of formula (I) by converting one or more of the radicals R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 and R_{10} (if present) into other radicals R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_9 , and R_{10} respectively, or
5 adding a further R_{10} radical, or removing an R_{10} radical, using known procedures.

The coupling reaction between the compound of formula (II), either (II_a) or (II_b), and the compound of formula (III), to form an amide bond, is preferably performed in the presence of a coupling agent, as are well known to the skilled in medicinal chemistry. Among others, the following coupling agents may be used: ethyl-
10 (*N,N'*-dimethylamino)propylcarbodiimide hydrochloride (also known as EDC.HCl), or (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate) (also known as HATU). Also, the coupling reaction can be performed using trimethylaluminium (AlMe₃) as coupling aid.

Compounds (II) and (III) are suitably reacted in the presence of a
15 coupling agent and in the presence of a base. Suitable bases include, but are not limited to, *N,N*-diisopropylethylamine (DIPEA), triethylamine (TEA), 4-dimethylaminopyridine (DMAP), or mixtures thereof.

The coupling reaction can take place in an inert organic solvent. Suitable organic solvents are, for example, aromatic hydrocarbons such as benzene, toluene or
20 xylene; halogenated hydrocarbons such as dichloromethane, chloroform or dichloroethane; ethers, such as tetrahydrofuran (THF), dioxane, diethylether or diisopropyl ether; nitriles such as acetonitrile or propionitrile; ketones such as acetone, methyl ethyl ketone or diethyl ketone; alcohols, such as methanol, ethanol, *n*-propanol, isopropanol or *n*-butanol; and also dimethylformamide (DMF) or dimethylsulfoxide
25 (DMSO), or mixtures thereof. Preferred solvents are dichloromethane, toluene, tetrahydrofuran and dimethylformamide.

A preferred method for carrying out the coupling reaction of compound (II) with compound (III), as defined above, involves using the coupling agent HATU, more preferably in the presence of the base DIPEA. Preferably, the reaction is carried
30 out using dimethylformamide as solvent, and at about room temperature.

Another preferred method for carrying out the coupling reaction of compound (II) with compound (III), as defined above, involves using the coupling agent EDC.HCl, more preferably in the presence of the base DMAP, and optionally in the presence of hydroxybenzotriazole (HOBt). Preferably, the reaction is carried out using
35 dichloromethane as solvent, and at about room temperature.

Another preferred method for carrying out the coupling reaction of compound (II_b) with compound (III), for example when R₁₆ is methyl or ethyl, involves using trimethylaluminium as a coupling aid. Preferably, this reaction can be carried out in presence of triethylamine. The solvent is preferably selected from toluene, tetrahydrofuran or mixtures thereof. Preferably the solvent is toluene. The reaction is preferably carried out at a temperature in the range 50-130 °C. For example, the reaction can be carried out in a microwave reactor.

It will be appreciated that while some preferred conditions are herewith disclosed for carrying out the processes, such as temperature, reagents, or solvents, for example, it will be matter of routine for the skilled in the art to adjust such conditions to each particular case to achieve optimized results.

Compounds of formula (II) and formula (III) are either commercially available or can be prepared using methods known to the skilled in the art.


For example, a compound of formula (II_a) can be obtained from a compound of formula (II_b) by attaching a group R₈ to the N atom of the pyrrolidine ring using known methods.

For example, when R₈ is a C₁₋₆alkyl the compound of formula (II_a) can be obtained by N-alkylation of pyrrolidine according to methods well known in the art, for example, using alkyl halides or alcohols as alkylating agents, or by reductive alkylation by means of an aldehyde or ketone in the presence of a reducing agent.

When R₈ is a -CONH₂ group, the compound of formula (II_a) can be obtained, for example, by reacting the corresponding compound of formula (II_b) with potassium cyanate (KOCN).

When R₈ is a -CONR₁₃R₁₄ group, the compound of formula (II_a) can be obtained, for example, by reacting the corresponding compound of formula (II_b) with ClCONR₁₃R₁₄.

Alternatively, when R₈ is a -CONR₁₃R₁₄ group, the compound of formula (II_a) can be obtained, for example, by a transacylation reaction promoted by carbonyldiimidazole, as represented in Scheme III:



SCHEME III

The compounds of the invention, as well as the intermediate products, can be prepared by the methods described herein, or small variations thereof, as well as using alternative methods, as will be matter of routine to the skilled in the art.

The following examples are provided by way of illustration and should not be construed as limiting the present invention.

Examples

Abbreviations:

- Boc: *tert*-butoxycarbonyl
- (Boc)₂O or Boc anhydride: di-*tert*-butyl dicarbonate
- Cbz: carboxybenzyl
- DCM: dichloromethane
- DIPEA: *N,N*-diisopropylethylamine
- DMF: dimethylformamide
- EDC.HCl: ethyl-(*N,N'*-dimethylamino)propylcarbodiimide hydrochloride
- EtOAc: ethyl acetate
- HATU: (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate)
- LiHMDS: lithium bis(trimethylsilyl)amide
- mCPBA: *meta*-chloroperoxybenzoic acid
- MeOH: methanol
- Pd/C: palladium on activated charcoal
- TEA: triethylamine
- THF: tetrahydrofuran

General methods:

Moisture and oxygen sensitive reactions were conducted in dry glassware (Schlenk flasks sealed with rubber septa) under nitrogen.

5

Solvents

All solvents used were of analytical-grade quality and if not otherwise mentioned demineralised water was used.

Water-free solvents were freshly distilled under N₂ atmosphere prior to use.

10

- Tetrahydrofuran (THF) from sodium–benzophenone ketyl,
- Methanol from magnesium methanolate,
- Dichloromethane (CH₂Cl₂) from calcium hydride.

HPLC solvents were of gradient-grade quality and double distilled water was used. All eluents were degassed by sonication prior to use.

15

Thin layer chromatography (TLC)

Thin layer chromatography was conducted with TLC silica gel 60 F₂₅₄ on aluminium sheets (Merck) in a saturated chamber at room temperature.

20

The spots were visualized under UV light (254 nm) and with reagents such as iodine vapour with additional heating.

As the R_F-value strongly depends on the exact ratio of the components of the eluent and some of these components are highly volatile, the given R_F-values represent just approximate values.

25

Flash column chromatography (fc)

Flash column chromatography (fc) was conducted with silica gel (100 – 200 µm) (Spectrochem) as stationary phase. Compressed air was used to push the solvent through the column.

30

HPLC method

Model: Waters 2695 Separation Module

Column: Waters XTerra® MS C18 (5 µm)
2.1 x 250 mm Column

35 Solvent: A: acetonitrile with 0.05% (v/v) formic acid.

B: water with 0.05% (v/v) formic acid

Gradient:

time [min]	solvent A [%]	solvent B [min]
0.0	5.0	95.0
3.0	5.0	95.0
10.0	100.0	0.0
15.0	100.0	0.0
17.0	5.0	95.0
18.0	5.0	95.0

Flow rate: 0.30 mL/min

5 Injection: volume: 2.0 μ L

Wavelength: 210 – 240 nm

Baseline auto zero: 0.0 min

Calculation: use blank subtraction from same series

Integration: manual

10 Calculation method: area %

All HPLC methods were performed at room temperature.

Mass spectrometry

15 The mass spectra were recorded with a Micromass Quatro *micro*TM API mass spectrometer. As all samples were measured in the positive and negative ion mode, all specified fragments display positively charged ions or radicals. The mass-to-charge ratios m/z and the relative signal intensities [%] of the ions are given.

NMR spectroscopy

20 ¹H NMR (500 MHz) spectra were recorded on a *Brucker UltraShield* (500 MHz), operating at 23 °C. Chemical shifts δ are reported in parts per million (ppm) against the reference compound tetramethylsilane and calculated using the chemical shift of the signal of the undeuterated solvent.

Abbreviations for the multiplicities of the signals:

25 s=singlet, d=doublet, t=triplet, q=quartet, quint=quintet, m=multiplet, dd=doublet of doublets etc.

Intermediate-1: Methyl 5-oxopyrrolidine-2-carboxylate

To a stirred solution of 5-oxopyrrolidine-2-carboxylic acid (10 g, 77.4 mmol) in MeOH (100 mL) thionyl chloride (6.7 mL, 92.9 mmol) was added at 0 °C and the reaction mixture was stirred at 70 °C for 16 h. The progress of the reaction was monitored by TLC. The excess of MeOH was evaporated, the residue was diluted with EtOAc (2x25 mL), the combined organic layer was stirred over K₂CO₃ (3 g), washed with water (20 mL) and brine (20 mL) and separated the organic layer, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound (4.3 g, 39% yield) as brown liquid.

¹H NMR (500 MHz, CDCl₃) δ: 6.12 (s, 1H), 4.27 (q, *J*=5.44 Hz, 1H), 3.79 (s, 3H), 2.51-2.41 (m, 1H), 2.43-2.37 (m, 2H), 2.34-2.24 (m, 1H).


Intermediate-2: 1-*tert*-butyl-2-methyl-5-oxopyrrolidine-1,2-dicarboxylate

To a stirred solution of methyl 5-oxopyrrolidine-2-carboxylate (Intermediate-1) (4.3 g, 30.06 mmol) in DCM (43 mL), DMAP (3.6 g 29.50 mmol) was added, followed by TEA (8.39 mL, 64.79 mmol) and Boc-anhydride (20.7 mL, 90.10 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with DCM (50 mL), washed with aqueous 1N HCl solution (20 mL) followed by brine (20 mL). The organic layer was separated, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound (6.8 g, 93% yield) as brown liquid.

¹H NMR (400 MHz, CDCl₃) δ 4.62 (dd, *J*=9.32, 2.68 Hz, 1H), 3.77 (s, 3H), 2.70-2.60 (m, 1H), 2.58-2.44 (m, 1H), 2.35-2.28 (m, 1H), 2.06-1.99 (m, 1H), 1.5 (s, 9H).

Intermediate-3: Methyl 1,5-dimethylpyrrolidine-2-carboxylate

The title intermediate was prepared from Intermediate-2 (1-*tert*-butyl-2-methyl-5-oxopyrrolidine-1,2-dicarboxylate) according to the procedure depicted in Scheme IV.



SCHEME IV

Step 1: Preparation of methyl 2-(tert-butoxycarbonylamino)-5-oxohexanoate

To a stirred solution of 1-*tert*-butyl-2-methyl-5-oxopyrrolidine-1,2-dicarboxylate (6.8 g, 27.89 mmol) in THF (68 mL), CH_3MgBr (3M in ether, 12.12 mL, 36.36 mmol) was added at 0 °C under inert atmosphere and the reaction mixture was stirred for 2 h at the same temperature. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with aqueous NH_4Cl solution and the aqueous layer was extracted with EtOAc (2x50 mL). The combined organic layer was washed with water (20 mL) and brine (20 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound (3.6 g, 49% yield) as yellow liquid.

^1H NMR (400 MHz, CDCl_3) δ 5.10 (bs, 1H), 4.25 (s, 1H), 4.12 (d, $J=7.04$ Hz, 1H), 3.73 (s, 3H), 2.59-2.47 (m, 2H), 2.1 (s, 2H), 2.03 (s, 1H), 1.89-1.84 (m, 1H), 1.4 (s, 9H)

Step 2: Preparation of methyl 5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylate

To a stirred solution of methyl 2-(*tert*-butoxycarbonylamino)-5-oxohexanoate (6.8 g, 27.89 mmol) in DCM (36 mL), trifluoroacetic acid (5.3 mL, 40.9 mmol) at 0 °C was added and the reaction mixture was stirred for 2 h at room temperature. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure to afford the title compound (3.6 g, 28% yield) as yellow liquid. The crude compound was used in the next step without purification.

Step 3: Preparation of methyl 5-methylpyrrolidine-2-carboxylate

To a stirred solution of methyl 5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylate (3.6 g, 25.53 mmol) in ethanol (36 mL), Pd/C (10% wet, 1 g) was added under nitrogen atmosphere and the reaction mixture was stirred under hydrogen atmosphere for 16 h at room temperature. The progress of the reaction was monitored by TLC. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure to afford the title compound (3.5 g, 95% yield) as brown liquid. The crude compound was used in the next step without purification.

Step 4: Preparation of methyl 1,5-dimethylpyrrolidine-2-carboxylate

To a stirred solution of methyl 5-methylpyrrolidine-2-carboxylate (2.2 g, 13.99 mmol) in MeOH (15.4 mL) NaHCO₃ (1.29 g, 15.38 mmol) was added at 0 °C. After stirring the reaction mixture for 5 min, aqueous formaldehyde (37%wt, 1.14 mL, 30.76 mmol) was added and stirring was continued for 2 h followed by the addition of NaBH₄ (0.876 g, 23 mmol) at same temperature. The reaction mixture was stirred for another 1 h at room temperature. The progress of the reaction was monitored by TLC. Excess of MeOH was evaporated, the residue was diluted with water (20 mL), and extracted with EtOAc (2x20 mL). The combined organic layer was washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound as pale brown liquid.

¹H NMR (400 MHz, CDCl₃) δ 3.75 (t, *J*=9.08 Hz, 3H), 2.92 (t, *J*=8.32 Hz, 1H), 2.32 (s, 3H), 2.04-1.92 (m, 1H), 1.87-1.85 (m, 3H), 1.28-1.25 (m, 1H), 1.15 (d, *J*=5.96 Hz, 3H)

Intermediate-4: (R)-1-carbamoylpyrrolidine-2-carboxylic acid

To a stirred solution of D-Proline (1 g, 8.69 mmol) in water (50 mL) concentrated HCl (pH~5) was added, followed by KOCN (2.11 g, 26.01 mmol) and the reaction mixture was stirred at 60 °C for 4 h. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature, acidified with concentrated HCl (pH~4), the solid formed was filtered, washed with ice-cold water (2x100 mL) and dried under vacuum to afford the title compound (460 mg, 33% yield) as white solid.

Intermediate-5: (S)-1-carbamoylpyrrolidine-2-carboxylic acid

The title compound (500 mg, 36% yield) was prepared following an analogous procedure as for Intermediate-4, but using L-Proline (1 g, 8.69 mmol), as starting material.

5

Intermediate-6: 1-carbamoylpyrrolidine-2-carboxylic acid

The title compound (500 mg, 14% yield) was prepared from DL-proline (2.5 g, 21.7 mmol), following an analogous procedure as for Intermediate-4.

¹H NMR (400 MHz, DMSO-d₆) δ 12.35 (s, 1H), 5.85 (s, 2H), 4.15 (d, J=8.44Hz, 1H), 3.25 (m, 1H), 2.05 (m, 1H), 1.8 (d, J=5.2 Hz, 3H).

10

Intermediate-7: (2S,4S)-1-carbamoyl-4-fluoropyrrolidine-2-carboxylic acid

The title compound (260 mg, 79% yield) was prepared from (2S,4S)-4-fluoropyrrolidine-2-carboxylic acid (260 mg, 1.87 mmol), following an analogous procedure as for Intermediate-4.

15

Intermediate-8: Methyl pyrrolidine-2-carboxylate

To a stirred solution of pyrrolidine-2-carboxylic acid (1 g, 8.69 mmol) in MeOH (10 mL) thionyl chloride (0.75 mL, 10.43 mmol) was added and the reaction mixture was stirred at reflux temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated, the residue was diluted with DCM (15 mL), the excess of thionyl chloride was quenched with solid NaHCO₃, filtered, and the filtrate was concentrated under reduced pressure to afford the title compound (1.1 g, 98% yield) as pale yellow solid.

20

25

Intermediate-9: 1-tert-butyl 2-methyl pyrrolidine-1,2-dicarboxylate

To a stirred solution of methyl pyrrolidine-2-carboxylate (Intermediate-8) (1 g, 7.74 mmol) in DCM (10 mL) TEA (2.7 mL) was added, followed by di-tert-butyl dicarbonate (Boc anhydride, (Boc)₂O) (1.86 g, 8.51 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with water (20 mL) and extracted with chloroform (2x20 mL). The combined organic layer was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography

30

(silica gel 100-200 mesh) to afford the title compound (1.3 g, 73% yield) as pale yellow liquid.


Intermediate-10: 1-*tert*-butyl 2-methyl 2-methylpyrrolidine-1,2-dicarboxylate

To a stirred solution of 1-*tert*-butyl 2-methyl pyrrolidine-1,2-dicarboxylate (Intermediate-9) (2.75 g, 12.00 mmol) in THF (5.5 mL), LiHMDS (Lithium bis(trimethylsilyl)amide) (1 M in n-hexane, 19.21 mL, 19.23 mmol) was added at -20 °C. After stirring the reaction mixture for 1.5 h at same temperature, iodomethane (MeI) (2.72 g, 19.16 mmol) was added and stirring was continued at room temperature for 18 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with NH₄Cl solution and extracted with EtOAc (2x30 mL). The combined organic layer was washed with water (15 mL) and brine (15 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel 100-200 mesh) to afford the title compound (1.5 g, 51% yield) as pale yellow liquid.

GCMS m/z: 243

Intermediate-11: Methyl 1-hydroxypyrrolidine-2-carboxylate

The title compound was prepared from methyl pyrrolidine-2-carboxylate (Intermediate-8) according to the procedure depicted in Scheme V:



SCHEME V

Step 1: Preparation methyl 1-(2-cyanoethyl)pyrrolidine-2-carboxylate

To a stirred solution of methyl pyrrolidine-2-carboxylate (Intermediate-8) (250 mg, 1.937 mmol) in MeOH (2 mL), acrylonitrile (0.15 mL, 2.264 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure to afford the title compound (200 mg, 56% yield) as colourless liquid. The crude compound was used in the next step without purification.

¹H NMR (400 MHz, CDCl₃) δ 3.75 (s, 3H), 3.35 (bs, 1H), 3.22-3.20 (m, 1H), 3.19-3.10 (m, 1H), 2.86-2.81 (m, 1H), 2.58-2.55 (m, 3H), 2.15-2.13 (m, 1H), 2.00-1.85 (m, 3H).

5 *Step 2: Preparation of methyl 1-hydroxypyrrolidine-2-carboxylate*

To a stirred solution of methyl 1-(2-cyanoethyl)pyrrolidine-2-carboxylate (1 g, 5.49 mmol) in DCM (15 mL), mCPBA (1.9 g 8.715 mmol) was added at 0 °C and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced
10 pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound (150 mg, 18% yield) as colourless liquid.


¹H NMR (400 MHz, DMSO-*d*₆) δ 8.1 (s, 1H), 3.6 (s, 3H), 3.4 (t, *J*=7.8 Hz, 1H), 3.03-3.08 (m, 1H), 2.7 (q, *J*=8.24 Hz, 1H), 2.05-1.98 (m, 1H), 1.77-1.71 (m, 3H).

15 **Intermediate-12: Methyl 1-(dimethylcarbamoyl)pyrrolidine-2-carboxylate**

To a stirred solution of methyl pyrrolidine-2-carboxylate (200 mg, 1.74 mmol) in DCM (10 mL) TEA (0.72 mL, 5.27 mmol) was added, followed by dimethylcarbamic chloride (0.19 mL, 2.08 mmol) and the reaction mixture was stirred at room temperature for 2 h. The progress of the reaction was monitored by TLC. The
20 reaction mixture was diluted with water (10 mL) and extracted with DCM (2x15 mL). The combined organic layer was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the title compound (180 mg, 51% yield) as off-white solid.

25 **Intermediate-13: *tert*-butyl 4-(2-(methoxycarbonyl)pyrrolidine-1-carbonyl)piperazine-1-carboxylate**

The title compound was prepared according to the procedure depicted in Scheme VI:



SCHEME VI

Step 1: Preparation tert-butyl 4-(1H-imidazole-1-carbonyl)piperazine-1-carboxylate

5 To a stirred solution of carbonyldiimidazole (5 g, 30.84 mmol) in DCM (50 mL) TEA (4.33 mL, 30.83 mmol) and Boc-piperazine (5.74 g, 30.83 mmol) were added and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with water (50 mL) and extracted with DCM (2x50 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the title compound (3 g, crude) as off-white solid. The crude compound was used in the next step without purification.

10

Step 2: Preparation of 1-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)-3-methyl-1H-imidazol-3-ium iodide

15

To a stirred solution of *tert*-butyl 4-(1H-imidazole-1-carbonyl)piperazine-1-carboxylate (3 g, 10.67 mmol) in acetonitrile (15 mL), iodomethane (2.64 mL, 42.70 mmol) was added at 0 °C and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The solvent was evaporated under reduced pressure to afford the title compound (3 g, crude) as off-white solid. The crude compound was used in the next step without purification.

20


Step 3: Preparation tert-butyl 4-(2-(methoxycarbonyl)pyrrolidine-1-carbonyl)piperazine-1-carboxylate

25 To a stirred solution of 1-(4-(*tert*-butoxycarbonyl)piperazine-1-carbonyl)-3-methyl-1H-imidazol-3-ium iodide (3 g, 10.16 mmol) in DCM (30 mL), TEA (1.42 mL,

50.84 mmol) and pyrrolidine-2-carboxylic acid methyl ester (2.62 g, 20.35 mmol) were added and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with water (50 mL), and extracted with DCM (2x50 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography to afford the title compound (1 g, 29% yield) as off-white solid.

Intermediate-14: Methyl 1-(morpholine-4-carbonyl)pyrrolidine-2-carboxylate

The title compound was prepared according to the procedure depicted in Scheme VII:



SCHEME VII

15

Step 1: Preparation of (1H-imidazol-1-yl)(morpholino)methanone

To a stirred solution of carbonyldiimidazole (5 g, 30.83 mmol) in DCM (50 mL), TEA (4.3 mL, 30.83 mmol), and morpholine (2.5 g, 29.06 mmol) were added and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with water (20 mL) and extracted with DCM (2x50 mL). The combined organic layer was washed with water (20 mL) and brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the title compound (3 g, crude) as off-white solid. The crude compound was used in the next step without purification.

25

Step 2: Preparation of (3-methyl-1-(morpholine-4-carbonyl)-1H-imidazol-3-ium iodide

To a stirred solution of (1H-imidazol-1-yl)(morpholino)methanone (3 g, 16.55 mmol) in acetonitrile (15 mL) iodomethane (4.1 mL, 66.22 mmol) was added at 0

°C and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The solvent was evaporated under reduced pressure to afford the title compound (2 g, crude) as off-white solid. The crude compound was used in the next step without purification.

5

Step 3: Preparation of methyl 1-(morpholine-4-carbonyl)pyrrolidine-2-carboxylate

To a stirred solution of (3-methyl-1-(morpholine-4-carbonyl)-1H-imidazol-3-ium iodide (2 g, 10.16 mmol) in DCM (30 mL) TEA (7.1 mL, 50.84 mmol) and pyrrolidine-2-carboxylic acid methyl ester (2.62 g, 20.35 mmol) were added and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with water (20 mL) and extracted with DCM (2x25 mL). The combined organic layer was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography to afford the title compound (1 g, 41% yield) as off-white solid.

15

Intermediate-15: Ethyl 1-methyl-5-oxopyrrolidine-2-carboxylate

To a stirring solution of sodium hydride (2 equiv) in anhydrous DMF (2 mL) at ice cooled condition under argon atmosphere, a solution of ethyl 5-oxopyrrolidine-2-carboxylate (300 mg in 3 mL DMF) was added dropwise over a time period of 10 min, and the reaction mixture was stirred for 15 min at the same temperature. Next, iodomethane was added and allowed to stirring for 3 h. To quench the reaction a saturated solution of NH₄Cl (5 mL) was added and extracted with DCM (2 x 10 mL). The combined organic portion was dried over anhydrous sodium sulfate and distilled out under reduced pressure to obtain the title compound (175 mg).

20

LC-MS: 172.2 (M+H).

Intermediate-16: 1,2-dimethylpyrrolidine-2-carboxylic acid

The title compound was obtained by N-methylation of 2-methylpyrrolidine-2-carboxylic acid. Thus, to a stirred solution of 2-methylpyrrolidine-2-carboxylic acid (300 mg) in anhydrous MeOH (10 mL), 1 mL of formaldehyde was added dropwise at 0 °C, followed by a catalytic amount of acetic acid, and the reaction mixture was stirred for 10 min at the same temperature. Next, 50 mg of 10% Pd/C was added and the reaction mixture was stirred at room temperature in presence of hydrogen atmosphere for 2 h. The progress of the reaction was monitored by TLC.

35

After complete consumption of starting materials, the reaction mixture was filtered through a celite bed to remove the solid residue which was washed with MeOH for several times. The filtrate was collected and concentrated under reduced pressure to obtain the title compound (300 mg).

5 LC-MS: 144.18 (M+H)

Intermediate-17: 4-fluoro-1-methylpyrrolidine-2-carboxylic acid

The title compound was obtained by N-methylation of 4-fluoropyrrolidine-2-carboxylic acid, following an analogous procedure as disclosed above for the preparation of Intermediate-16. 150 mg of 4-fluoropyrrolidine-2-carboxylic acid afforded 120 mg of the title compound.

LC-MS: 148.2 (M+H).

Intermediate-18: 3-methyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid

15 The title compound was obtained by N-methylation of 3-azabicyclo[3.1.0]hexane-2-carboxylic acid, following an analogous procedure as disclosed above for the preparation of Intermediate-16. 300 mg of 3-azabicyclo[3.1.0]hexane-2-carboxylic acid afforded 300 mg of the title compound.

LC-MS: 144.18 (M+H).

20

Intermediate-19: 1,4-dimethylpyrrolidine-2-carboxylic acid

The title compound was obtained by N-methylation of 4-methylpyrrolidine-2-carboxylic acid, following an analogous procedure as disclosed above for the preparation of Intermediate-16. 250 mg of 4-methylpyrrolidine-2-carboxylic acid afforded 250 mg of the title compound.

25

LC-MS: 144.18 (M+H)

Intermediate-20: 1,3-dimethylpyrrolidine-2-carboxylic acid

30 The title compound was obtained by N-methylation of 3-methylpyrrolidine-2-carboxylic acid, following an analogous procedure as disclosed above for the preparation of Intermediate-16. 250 mg of 3-methylpyrrolidine-2-carboxylic acid afforded 250 mg of the title compound.

LC-MS: 144.18 (M+H)


Intermediate-21: 1-ethylpyrrolidine-2-carboxylic acid

The title compound was obtained by N-ethylation of pyrrolidine-2-carboxylic acid, following an analogous procedure as in the N-methylation disclosed above for the preparation of Intermediate-16, but using acetaldehyde instead of formaldehyde. 1 g of pyrrolidine-2-carboxylic acid afforded 187 mg of the title compound.

LC-MS: 144.18 (M+H)

Intermediate-22: 1-(benzyloxycarbonyl)pyrrolidine-2-carboxylic acid

A mixture of pyrrolidine-2-carboxylic acid (2.5 g, 21.7 mmol), NaOH (2 M solution, 10 mL) and carbobenzoxy chloride (3.7 g, 21.7 mmol) were stirred at room temperature for 6 h. The progress of the reaction was monitored by TLC. The reaction mixture was acidified with 2N HCl and extracted with EtOAc (2x50 mL). The combined organic layer was washed with water (15 mL) and brine (15 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the title compound (1.5 g, 27% yield) as colourless liquid.

Example 1: N'-(4-fluorophenyl)-1,5-dimethylpyrrolidine-2-carbohydrazide

To a stirred solution of methyl 1,5-dimethylpyrrolidine-2-carboxylate (Intermediate-3) (0.3 g, 1.91 mmol) in toluene (6 mL) 4-fluorophenylhydrazine hydrochloride (0.31 g, 1.91 mmol), TEA (0.536 mL, 4.13 mmol) and trimethylaluminum (2M solution in toluene, 0.96 mL, 1.91 mmol) at 0 °C were added and the reaction mixture was stirred at 70 °C in microwave for 1 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with ice-cold water (5 mL), extracted with EtOAc (2x20 mL). The combined organic layer was washed with water (5 mL) and brine (5 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound (18 mg, 3% yield) as pale brown solid.


¹H NMR (400 MHz, DMSO-d₆) δ 9.98 (s, 1H), 7.64 (s, 1H), 6.95 (t, J=8.72 Hz, 2H), 6.7 (q, 4.68 Hz, 2H), 3.4 (s, 1H), 3.1 (s, 1H), 2.3 (s, 3H), 2.05-2.00 (m, 2H), 1.68-1.65 (m, 1H), 1.40-1.30 (m, 1H), 0.93 (d, J=6 Hz, 3H)

LC-MS m/z (M+H): 252.2

Purity (HPLC): 99.3%

Example 2: (R)-2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide

5



To a stirred solution of (*R*)-1-carbamoylpyrrolidine-2-carboxylic acid (Intermediate-4) (500 mg, 3.16 mmol) in DMF (5 mL) DIPEA (1.61 mL, 9.23 mmol), HATU (1.44 g 3.79 mmol) and 4-fluorophenylhydrazine hydrochloride (563 mg, 3.48 mmol) were added at 0 °C under nitrogen atmosphere and the reaction mixture was stirred at room temperature for 3 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with ice-cold water (25 mL) and extracted with EtOAc (2x15 mL). The combined organic layer was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound (28 mg) as off-white solid.


¹H NMR (400 MHz, DMSO-*d*₆) δ 9.61 (d, *J*=2.6Hz, 1H), 7.59 (d, *J*=2.4Hz, 1H), 6.91 (t, *J*=8.8 Hz, 2H), 6.75-6.72 (m, 2H), 5.85 (s, 2H), 4.21-4.18 (m, 1H), 3.41-3.30 (m, 1H), 3.25-3.19 (m, 1 H), 2.09-1.97 (m, 1H), 1.94-1.78 (m, 3H)

LC-MS m/z (M-H): 265.1

Purity (HPLC): 99.8%

Example 3: (S)-2-(2-(4-fluorophenyl) hydrazinecarbonyl) pyrrolidine-1-carboxamide

25



The title compound was prepared following an analogous procedure as in Example 2, but using (*S*)-1-carbamoylpyrrolidine-2-carboxylic acid (Intermediate-5)

as starting material. 500 mg of Intermediate-5 afforded 35 mg (4% yield) of the title compound as a off-white solid.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.62 (s, 1H), 7.60 (s, 1H), 6.91 (t, $J=8.88$ Hz, 2H), 6.75-6.72 (m, 2H), 5.86 (s, 2H), 4.21-4.18 (m, 1H), 3.38-3.31 (m, 1H),
5 3.25-3.19 (m, 1H), 2.06-1.91 (m, 1H), 1.89-1.79 (m, 3H)


LC-MS m/z (M-H): 265.0

Purity (HPLC): 99.6%

Examples 4-12

10 Examples 4-12 were prepared following analogous procedures as the one disclosed for Example 2, using 1-carbamoylpyrrolidine-2-carboxylic acid (Intermediate-6) and the suitable hydrazine as starting materials:

Example 4: 2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide




^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.6 (s, 1H), 7.6 (s, 1H), 6.9 (t, $J=8.88$ Hz, 2H), 6.80-6.70 (m, 2H), 5.85 (s, 2H), 4.2 (dd, $J=3.04$ Hz, $J=8.44$ Hz, 1H), 3.4-3.3 (m, 1H), 3.3-3.2 (m, 1H), 2.1-2.0 (m, 1H), 1.90-1.70 (m, 3H)

LC-MS m/z (M-H): 265

20 Purity (HPLC): 99.0%

Melting point: 140-144°C

Example 5: 2-(2-(4-fluoro-2-methylphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide




^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.63 (d, $J=2.3$ Hz, 1H), 6.91(d, $J=2.1$ Hz, 1H), 6.85-6.72 (m, 3H), 5.85 (s, 2H), 4.25-4.22 (m, 1H), 3.42-3.38 (m, 1H), 3.29-3.20 (m, 1H), 2.12 (s, 3H), 2.07-1.97 (m, 1H), 1.96-1.83 (m, 3H)

LC-MS m/z (M-H): 279.2

Purity (HPLC): 99.8%

Example 6: 2-(2-(3,5-difluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide



5


^1H NMR (400 MHz, DMSO- d_6) δ 9.73 (s, 1H), 8.22 (s, 1H), 6.40-6.33 (m, 3H), 5.90 (s, 2H), 4.19-4.16 (m, 1H), 3.41-3.36 (m, 1H), 3.24-3.20 (m, 1H), 2.09-2.02 (m, 1H), 1.95-1.80 (m, 3H)

LC-MS m/z (M-H): 283.1

10

Purity (HPLC): 99.6%

Example 7: 2-(2-(4-(trifluoromethoxy)phenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide



15


^1H NMR (400 MHz, DMSO- d_6) δ 9.67 (d, $J=2.0\text{Hz}$, 1H), 7.89 (d, $J=1.9\text{Hz}$, 1H), 7.06 (d, $J=8.6\text{Hz}$, 2H), 6.79 (d, $J=8.9\text{Hz}$, 2H), 5.86 (s, 2H), 4.22-4.19 (m, 1H), 3.41-3.36 (m, 1H), 3.29-3.20 (m, 1H), 2.08-2.01 (m, 1H), 1.92-1.78 (m, 3H)

LC-MS m/z (M-H): 331.1

Purity (HPLC): 99.3%

20

Example 8: 2-(2-(4-(trifluoromethyl)phenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide




¹H NMR (400 MHz, DMSO-*d*₆) δ 9.77 (s, 1H), 8.29 (s, 1H), 7.38 (d, *J*=8.3Hz, 2H), 6.84 (d, *J*=8.3Hz, 2H), 5.86 (s, 2H), 4.23-4.20 (m, 1H), 3.39 (s, 1H), 3.29-3.20 (m, 1H), 2.12-2.03 (m, 1H), 1.95-1.81 (m, 3H)

LC-MS *m/z* (M-H): 315.2

5 Purity (HPLC): 99.8%

Example 9: 2-(2-(4-chloro-2-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide




10 ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.72 (s, 1H), 7.75 (s, 1H), 7.21 (d, *J*=10.7Hz, 1H), 7.19-6.92 (m, 2H), 5.87 (s, 2H), 4.22-4.19 (m, 1H), 3.41-3.35 (m, 1H), 3.29-3.20 (m, 1H), 2.07-2.00 (m, 1H), 1.95-1.79 (m, 3H)

LC-MS *m/z* (M-H): 299.1

Purity (HPLC): 99.9%

15

Example 10: 2-(2-(4-methoxyphenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide




20 ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.55 (d, *J*=2.7Hz, 1H), 7.28 (s, 1H), 6.77 (s, 4H), 5.84 (s, 2H), 4.21-4.19 (m, 1H), 3.65 (s, 3H), 3.38-3.31 (m, 1H), 3.24-3.18 (m, 1H), 2.05-1.90 (m, 1H), 1.88-1.79 (m, 3H)

LC-MS *m/z* (M-H): 277.0

Purity (HPLC): 99.7%

Example 11: 2-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)hydrazinecarbonyl)pyrrolidine-1-carboxamide




¹H NMR (400 MHz, DMSO-*d*₆) δ 9.51 (s, 1H), 7.21-6.95 (m, 1H), 6.58 (d, *J*=8.2Hz, 1H), 6.25-6.23 (m, 2H), 5.82 (s, 2H), 4.21-4.10 (m, 5H), 3.37-3.25 (m, 1H), 3.22-3.15 (m, 1H), 2.10-1.95 (m, 1H), 1.87-1.81 (m, 3H)

LC-MS *m/z* (M+H): 306.2

Purity (HPLC): 99.7%

Example 12: 2-(2-(4-sulfamoylphenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide




¹H NMR (400 MHz, DMSO-*d*₆) δ 9.77 (s, 1H), 8.29 (s, 1H), 7.51 (d, *J*=8.7Hz, 2H), 6.99 (s, 2H), 6.80 (d, *J*=8.6Hz, 2H), 5.88 (s, 2H), 4.23-4.20 (m, 1H), 3.41-3.36 (m, 1H), 3.26-3.20 (m, 1H), 2.09-2.02 (m, 1H), 1.94-1.80 (m, 3H)

LC-MS *m/z* (M-H): 326.1

Purity (HPLC): 98.2%

Example 13: (2*S*,4*S*)-4-fluoro-2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide




The title compound (30 mg) was prepared following an analogous procedure as in Example 2, but using (2*S*,4*S*)-1-carbamoyl-4-fluoropyrrolidine-2-carboxylic acid (Intermediate-7) (260 mg, 1.47 mmol) as starting material.

¹H NMR (400 MHz, DMSO-*d*₆) δ 9.58 (s, 1H), 7.57 (s, 1H), 6.92-6.88 (m, 2H), 6.70-6.75 (m, 2H), 5.99 (s, 2H), 5.38-5.24 (m, 1H), 4.36 (d, *J*=9.6Hz, 1H), 3.69-3.51 (m, 2H), 2.48-2.20 (m, 2H)

LC-MS *m/z* (M-H): 283.2

5 Purity (HPLC): 99.2%

Example 14: (*R*)-1-acetyl-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide




To a stirred solution of (*R*)-1-acetylpyrrolidine-2-carboxylic acid (50 mg, 0.31 mmol) in dry DMF (2 mL), DIPEA (82 mg, 0.63 mmol), HATU (181 mg, 0.47 mmol) and 4-fluorophenylhydrazine hydrochloride (65 mg, 0.37 mmol) were added at 0 °C and then the reaction mixture was stirred for 1 h at room temperature. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ice-cold water (10 mL), the solid formed was filtered and dried under vacuum to afford the title compound (30 mg, 35% yield) as off-white solid.

¹H NMR (400 MHz, CD₃OD) δ 6.95-6.84 (m, 4H), 4.45 (dd, *J*=3.8Hz, *J*=8.6Hz, 1H), 3.70-3.60 (m, 2H), 2.2-2.16 (m, 2H), 2.10 (s, 3H), 2.07-2.00 (m, 4H)

LC-MS *m/z* (M-H): 266.2

Purity (HPLC): 98.8%

Example 15: N'-(4-fluorophenyl)-1-hydroxypyrrolidine-2-carbohydrazide



To a stirred solution of methyl 1-hydroxypyrrolidine-2-carboxylate (Intermediate-11) (250 mg, 1.373 mmol) in dry toluene (5 mL), 4-fluorophenylhydrazine hydrochloride (223 mg, 1.37 mmol), TEA (0.355 mL, 2.74 mmol) and trimethylaluminium (2 M in toluene, 0.69 mL, 1.37 mmol) were added at 0 °C and the reaction mixture was stirred at 70 °C for 1.5 h in microwave. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with ice-cold water (20 mL); the aqueous layer was extracted with EtOAc (2x15 mL). The combined

organic layer was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound (30 mg, 7% yield) as off-white solid.


5 ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.4 (s, 1H), 8.15 (s, 1H), 7.65 (s, 1H), 6.95 (t, $J=8.84$ Hz, 2H), 6.7 (m, 2H), 3.3 (s, 1H), 3.15 (s, 1H), 2.7 (q, $J=8.76$ Hz, 1H), 2.1 (q, $J=9.76$ Hz, 1H), 1.81-1.65 (m, 3H)

LC-MS m/z ($M+H$): 240.2

Purity (HPLC): 98.8%

10

Example 16: N'-(4-fluorophenyl)-1,2-dimethylpyrrolidine-2-carbohydrazide



Method A

15 1,2-Dimethylpyrrolidine-2-carboxylic acid (Intermediate-16) (200 mg, 1.40 mmol) was dissolved in 7 mL of dry DCM, and subsequently TEA (3 equiv.), EDC.HCl (1.5 equiv.) and DMAP (1.5 equiv.) were added. After 10 min stirring at 0 °C, 4-fluorophenylhydrazine hydrochloride (1.5 equiv.) was added under argon atmosphere. After completion of the addition, the reaction mixture was stirred at room
20 temperature overnight. The solvent was removed and the residue was dissolved with 5% MeOH in DCM (20 mL) and washed with water (2 x 10 mL). The collected organic phase was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to obtain the title compound, which was purified by column chromatography (DCM: MeOH= 9.5:0.5) (42 mg, 12% yield).

25 ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 1.12 (s, 3H), 1.17-1.67 (m, 3H), 2.05 (s, 1H), 2.28 (s, 3H), 2.54-2.51 (m, 1H), 3.02 (d, $J = 1.5$ Hz, 1H), 6.70-6.58 (m, 2H), 6.99-6.96 (m, 2H), 7.51 (d, $J = 2.9$ Hz, 1H), 9.56 (d, $J = 2.8$ Hz, 1H) ppm


LC-MS: 252.4 ($M+H$)

Purity (HPLC): 96.0%

30

Method B

The title compound was prepared by coupling N-Boc protected methyl 2-methylpyrrolidine-2-carboxylate (Intermediate-10) with 4-fluorophenylhydrazine, followed by deprotection and methylation of the N-atom of the pyrrolidine ring, according to the process depicted in Scheme VIII:



SCHEME VIII

Step 1: Preparation of tert-butyl 2-(2-(4-fluorophenyl)hydrazinecarbonyl)-2-methylpyrrolidine-1-carboxylate

10 To a stirred solution of 1-*tert*-butyl 2-methyl 2-methylpyrrolidine-1,2-dicarboxylate (Intermediate-10) (3 g, 12.34 mmol) in toluene (24 mL) 4-fluorophenylhydrazine hydrochloride (2.4 g, 14.81 mmol) was added, followed by TEA (3.1 g, 30.69 mmol) and trimethylaluminium (2 M in toluene, 2.65 g, 36.80 mmol) at room temperature and the reaction mixture was stirred at 60 °C in microwave for 1 h.

15 The progress of the reaction was monitored by TLC. The reaction mixture was quenched with NH₄Cl solution and extracted with EtOAc (2x50 mL). The combined organic layer was washed with water (20 mL) and brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel 100-200 mesh) to afford the title compound (2.2 g, 53% yield) as off-white solid.

20

¹H NMR (400 MHz, CDCl₃) δ 9.13 (s, 1H), 6.94-6.92 (m, 2H), 6.81 (s, 2H), 6.00 (s, 1H), 3.51 (bs, 2H), 2.66 (s, 1H), 1.80 (s, 3H), 1.68 (s, 3H), 1.49 (s, 9H)

LC-MS m/z (M-H): 336.2

25 *Step 2: Preparation of N'-(4-fluorophenyl)-2-methylpyrrolidine-2-carbohydrazide*

To a stirred solution of *tert*-butyl 2-(2-(4-fluorophenyl)hydrazinecarbonyl)-2-methylpyrrolidine-1-carboxylate (2.2 g, 6.52 mmol)

in DCM (4 mL), trifluoroacetic acid (4.4 mL) was added at 0 °C and the reaction mixture was stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated, the residue was co-distilled with DCM (3x10 mL). The crude compound was neutralized with saturated NaHCO₃ solution (3 mL) and extracted with 10% MeOH/chloroform (2x 30 mL). The combined organic layer was washed with water (20 mL) and brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford the title compound (1 g, 64% yield) as brown solid.


10 **Step 3: Preparation of N'-(4-fluorophenyl)-1,2-dimethylpyrrolidine-2-carbohydrazide**

To a stirred solution of N'-(4-fluorophenyl)-2-methylpyrrolidine-2-carbohydrazide (1 g, 4.21 mmol) in acetonitrile (50 mL), K₂CO₃ (1.43 g, 10.51 mmol) was added, followed by iodomethane (0.313 mL, 5.07 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 12 h. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with water (30 mL) and extracted with EtOAc (2x20 mL). The combined organic layer was washed with water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel 100-200 mesh) to afford the title compound (350 mg, 33% yield) as brick red solid.

20 ¹H NMR (400 MHz, CDCl₃) δ 9.14 (s, 1H), 6.95-6.920 (m, 2H), 6.79-6.76 (m, 2H), 5.97 (s, 1H), 3.19-3.08 (m, 1H), 2.59-2.53 (m, 1H), 2.37 (s, 3H), 2.20 (s, 1H), 1.85-1.77 (m, 3H), 1.23 (s, 3H)

LC-MS m/z (M+H): 252.2

25 **Example 17: 2-(2-(4-fluorophenyl)hydrazinecarbonyl)-N,N-dimethylpyrrolidine-1-carboxamide**



The title compound was prepared following an analogous procedure as in Example 15, using methyl 1-(dimethylcarbamoyl)pyrrolidine-2-carboxylate (Intermediate-12) (100 mg, 0.49 mmol) as starting material. In this case, the reaction was carried out at 90 °C for 60 min, and the reaction mixture was quenched with


NH₄Cl. The crude compound was purified by preparative TLC to afford the title compound (30 mg, 20% yield) as off-white solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.44 (d, *J*=3.9 Hz, 1H), 6.97-6.90 (m, 2H), 6.88-6.75 (m, 2H), 5.97 (d, *J*=4.3Hz, 1H), 4.62 (t, *J*=7.9Hz, 1H), 3.50-3.40 (m, 2H),
 5 2.90 (s, 6H), 2.32-2.24 (m, 1H), 2.22-2.10 (m, 1H), 2.09-1.94 (m, 1H), 1.86-1.74 (m, 1H)


LC- MS *m/z* (M-H): 293.2

Purity (HPLC): 98.2%

10 **Example 18: N'-(4-fluorophenyl)-1-(piperazine-1-carbonyl)pyrrolidine-2-carbohydrazide hydrochloride**



The title compound was prepared by coupling the corresponding pyrrolidine intermediate (Intermediate-13), which carries a Boc protecting group on the piperazine ring, with 4-fluorophenylhydrazine, and subsequent deprotection, according to the process depicted in Scheme IX:



SCHEME IX

Step 1: Preparation of tert-butyl 4-(2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carbonyl)piperazine-1-carboxylate

The coupling reaction was performed following an analogous procedure as disclosed in Example 2, using *tert*-butyl 4-(2-(methoxycarbonyl)pyrrolidine-1-carbonyl)piperazine-1-carboxylate (Intermediate-13) (1 g, 2.92 mmol) as starting material, to afford the title compound (100 mg, 8% yield) as yellow solid.

5

Step 2: Preparation of N'-(4-fluorophenyl)-1-(piperazine-1-carbonyl)pyrrolidine-2-carbohydrazide hydrochloride

For the deprotection, a mixture of *tert*-butyl 4-(2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carbonyl)piperazine-1-carboxylate (100 mg, 0.22 mmol) in dioxane.HCl (1 mL) was stirred at room temperature for 5 h. The progress of the reaction was monitored by TLC. The solvent was evaporated under reduced pressure. The crude compound was washed with diethyl ether (5 mL) to afford the title compound (30 mg, 36% yield) as pale yellow solid.


¹H NMR (400 MHz, DMSO-*d*₆) δ 9.68 (s, 1H), 8.91 (bs, 2H), 7.66 (s, 1H), 6.97-6.93 (m, 2H), 6.70-6.67 (m, 2H), 4.32 (t, *J*=8.8 Hz, 1H), 3.47-3.31 (m, 5H), 3.08-3.02 (m, 4H), 2.21 (s, 1H), 1.91 (s, 1H), 1.74-1.69 (m, 2H)

15

LC-MS *m/z* (*M*+*H*): 373.0

Purity (HPLC): 99.5%

Example 19: 1-(4-acetylpiperazine-1-carbonyl)-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide hydrochloride



To a stirred solution of N'-(4-fluorophenyl)-1-(piperazine-1-carbonyl)pyrrolidine-2-carbohydrazide hydrochloride (Example 18) (200 mg, 0.53 mmol) in pyridine (2 mL) acetyl chloride (42 mg, 0.53 mmol) was added at 0 °C dropwise and the reaction mixture was stirred at room temperature for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was evaporated, the residue was quenched with ice cold-water (15 mL) and extracted with 10% MeOH/DCM (2x10 mL). The combined organic layer was washed with water (10 mL), brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced

30

pressure. The crude compound was dissolved in dioxane.HCl (10 mL) at room temperature and stirred for 10 min, the solvent was evaporated and washed with EtOAc (5 mL) to afford the title compound (50 mg, 22% yield) as white solid.


¹H NMR (400 MHz, DMSO-*d*₆) δ 9.63 (d, *J*=2.4Hz, 1H), 7.64 (d, *J*=2.0Hz, 1H), 6.93 (t, *J*=8.8Hz, 2H), 6.70-6.66 (m, 2H), 4.33 (t, *J*=4.4Hz, 1H), 3.46-3.44 (m, 3H), 3.39-3.35 (m, 3H), 3.29-3.20 (m, 1H), 3.19-3.14 (m, 3H), 2.18 (s, 1H), 1.97 (s, 3H), 1.91 (s, 1H), 1.74-1.61 (m, 2H)

LC-MS *m/z* (M+H): 415.1

Purity (HPLC): 99.8%

10

Example 20: N'-(4-fluorophenyl)-1-(morpholine-4-carbonyl)pyrrolidine-2-carbohydrazide hydrochloride



The title compound was prepared following an analogous procedure as in Example 15, using methyl 1-(morpholine-4-carbonyl)pyrrolidine-2-carboxylate (Intermediate-14) (1 g, 4.12 mmol) as starting material. The crude compound obtained was purified by column chromatography and the resulting compound was treated with dioxane hydrochloride for 15 min at room temperature and the solvent was evaporated to afford the title compound (30 mg) as off-white solid.


¹H NMR (400 MHz, DMSO-*d*₆) δ 9.62 (d, *J*=2.5Hz, 1H), 7.65 (d, *J*=2.5Hz, 1H), 6.96-6.92 (m, 2H), 6.70-6.67 (m, 2H), 4.32 (t, *J*=7.9Hz, 1H), 3.61-3.51 (m, 4H), 3.50-3.44 (m, 1H), 3.42-3.30 (m, 1H), 3.28-3.24 (m, 2H), 3.15-3.10 (m, 2H), 2.19-2.15 (m, 1H), 1.89 (s, 1H), 1.75-1.68 (m, 2H)

LC-MS *m/z* (M-H): 374.0

25

Purity (HPLC): 99.7%

Example 21: N'-(4-fluorophenyl)-1-methyl-5-oxopyrrolidine-2-carbohydrazide



To a solution of ethyl 1-methyl-5-oxopyrrolidine-2-carboxylate (Intermediate-15) (500 mg in 5 mL of toluene), trimethylaluminium (3 equiv.) was added at ice cold condition and stirred under argon atmosphere for 15 min. Then 4-fluorophenylhydrazine hydrochloride (1 equiv.) in 2 mL of toluene was added to the reaction mixture and refluxed at 120 °C for 4h. After the completion of the reaction, the reaction mixture was quenched with saturated NH₄Cl solution and extracted with EtOAc (3 x 15 mL). The collected organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography (DCM:MeOH = 9.7:0.3) and recrystallized with DCM and diethyl ether to obtain the title compound (25 mg, 3.15% yield).


¹H NMR (500 MHz, DMSO-*d*₆) δ 2.01 (s, 1H), 2.21 (s, 2H), 2.37 (s, 1H), 2.69 (s, 3H), 5.08 (d, *J* = 7.7 Hz, 1H), 5.41 (s, 2H), 7.22 (brs, 2H), 7.60 (brs, 2H) ppm

LC-MS (M+H): 252.2

Purity (HPLC): 95%

15

Example 22: N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide




The title compound was prepared using an analogous procedure as disclosed for Example 16 (method A), employing 1-methylpyrrolidine-2-carboxylic acid (400 mg) as starting product. The crude product obtained in the reaction was purified by column chromatography (DCM:MeOH= 9.5:0.5) to afford 27 mg of the title compound (3.7% yield).

¹H NMR (500 MHz, DMSO-*d*₆) δ 1.79 - 1.73 (m, 3H), 2.09 (s, 1H), 2.27-2.25 (m, 1H), 2.34 (s, 3H), 2.86-2.83 (m, 1H), 3.03 (s, 1H), 6.71 -6.67 (m, 2H), 7.00-6.96 (m, 2H), 7.62 (s, 1H), 9.61 (s, 1H) ppm

LC-MS (M+H): 238.8


Purity (HPLC): 95.0%

Example 23: 4-amino-N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide



30

The title compound was obtained by coupling 4-fluorophenylhydrazine with 4-amino-1-methylpyrrolidine-2-carboxylic acid, previously protecting the amine of the latter with a Boc protecting group, and deprotecting it after the coupling reaction, as depicted in Scheme X:



SCHEME X

Step 1: Preparation of 4-((tert-butoxycarbonyl)amino)-1-methylpyrrolidine-2-carboxylic acid

To solution of 4-amino-1-methylpyrrolidine-2-carboxylic acid (1 equiv.) in 60 mL dioxane:H₂O (2:3), Na₂CO₃ (3 equiv.) was added and stirred for 10 min at 0 °C. Then, to this reaction mixture Boc anhydride (1.1 equiv.) was added dropwise at the same temperature and allowed for stirring at room temperature overnight. After completion of the reaction, the reaction mixture was acidified with 1 N HCl to bring the pH at 3 and it was extracted with 10% MeOH in DCM (60 mL). The organic layer was dried over anhydride Na₂SO₄. The organic solvent was distilled out at reduced pressure to obtain the crude title compound which was purified by column chromatography (DCM: MeOH = 9.6:0.4) to afford the purified title compound (9.8% yield).

LC-MS (M+H): 245.3

Step 2: Preparation of tert-butyl (5-(2-(4-fluorophenyl)hydrazinecarbonyl)-1-methylpyrrolidin-3-yl)carbamate

The title compound was prepared using an analogous procedure as disclosed for Example 16 (method A), employing 4-((tert-butoxycarbonyl)amino)-1-methylpyrrolidine-2-carboxylic acid (100 mg) as starting product. The crude product

obtained in the reaction was purified by column chromatography (DCM:MeOH=9.5:0.5) to afford 50 mg of the title compound (34.71% yield).

LC-MS (M+H): 353.4

Purity (HPLC): 92.14%

5

Step 3: Preparation of 4-amino-N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide

For deprotection, 5 mL of 5 N HCL was added dropwise at 0 °C to a solution of *tert*-butyl (5-(2-(4-fluorophenyl)hydrazinecarbonyl)-1-methylpyrrolidin-3-yl)carbamate (1 equiv.) in 5 mL DCM, and the mixture was allowed to stirring for 4h. After complete consumption of starting material, the solvent was distilled out under reduced pressure to obtain a sticky solid which was dissolved in 10% MeOH in DCM and washed with saturated solution of NaHCO₃. The organic portion was collected and dried over Na₂SO₄, the organic portion was distilled out under reduced pressure to obtain the title compound (25 mg, 69.4%).


¹H NMR (500 MHz, DMSO-*d*₆) δ 1.65-1.4 (m, 1H), 2.37 (s, 3H), 2.47-2.41 (m, 3H), 2.77 (d, *J* = 9.05 Hz, 1H), 2.82 (t, *J* = 6.35 Hz, 1H), 6.74 -6.71 (m, 2H), 6.99 - 6.96 (m, 2H), 7.62 (s, 1H), 9.75 (brs, 1H) ppm; The NH₂ protons remain unsolved.

20

LC-MS (M+H): 253.4

Purity (HPLC): 95.0%

Example 24: 4-fluoro-N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide



25

The title compound was prepared using an analogous procedure as disclosed for Example 21, employing 4-fluoro-1-methylpyrrolidine-2-carboxylic acid (Intermediate-17) as starting material. 90 mg of 4-fluoro-1-methylpyrrolidine-2-carboxylic acid afforded the title compound as crude product. The crude product was purified by column chromatography using DCM as eluent to afford 20 mg of the title compound (13% yield).


30

¹H NMR (500 MHz, DMSO-*d*₆) δ 2.35-2.25 (m, 1H), 2.57 (s, 3H), 2.64-2.62 (m, 1H), 3.21 (d, *J* = 7.5 Hz, 1H), 3.47-3.45 (m, 1H), 5.22 (m, 1H), 5.97 (d, *J* = 3.5 Hz, 1H), 6.82-6.80 (m, 2H), 6.95-6.91 (m, 2H), 8.94 (s, 1H) ppm

LC-MS (M+H): 256.4

5 Purity (HPLC): 95.0%

Example 25: (S)-1-(cyclopropylmethyl)-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide



10 The title compound was prepared using an analogous procedure as disclosed for Example 16 (method A), employing (*R*)-1-(cyclopropylmethyl)pyrrolidine-2-carboxylic acid (120 mg) as starting material. The crude product was purified by column chromatography using DCM as eluent to afford 30 mg of the title compound (12.2% yield).


15 ¹H NMR (500 MHz, DMSO-*d*₆) δ 0.11 (s, 1H), 0.49-0.44 (m, 2H), 0.9-1.1 (m, 1H), 1.78-1.76 (m, 3H), 1.99-2.05 (m, 1H), 2.42-2.28 (m, 2H), 3.05 (s, 1H), 3.31 (s, 1H), 6.71-6.67 (m, 2H), 6.99-6.96 (m, 2H), 7.60 (s, 1H), 9.51 (s, 1H) ppm;

LC-MS (M+H): 278.2

Purity (HPLC): 96.2%

20

Example 26: N'-(4-fluorophenyl)-3-methyl-3-azabicyclo[3.1.0]hexane-2-carbohydrazide




25 The title compound was prepared using an analogous procedure as disclosed for Example 16 (method A), employing 3-methyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (Intermediate-18) (25 mg, 0.18 mmol) as starting material, which afforded 3 mg of the final product (7% yield).

^1H NMR (500 MHz, CDCl_3) δ 0.52 (d, J = 5.4 Hz, 1H), 0.78 (s, 1H), 1.16 (d, J = 4.0 Hz, 1H), 1.43 (t, J = 6.5 Hz, 1H), 2.73 (s, 3H), 2.59 (d, J = 6.4 Hz, 1H), 3.23-3.16 (m, 2H), 6.01 (s, 1H), 6.83-6.80 (m, 2H), 6.95 - 6.92 (m, 2H), 8.38 (s, 1H) ppm

LC-MS (M+H): 250.2

5 Purity (HPLC): 98.2%

Example 27: N'-(4-fluorophenyl)-1,4-dimethylpyrrolidine-2-carbohydrazide




The title compound was prepared using an analogous procedure as disclosed for Example 16 (method A), employing 1,4-dimethylpyrrolidine-2-carboxylic acid (Intermediate-19) (100 mg, 0.70 mmol) as starting material, which afforded 14 mg of the final product (9% yield).

^1H NMR (500 MHz, CDCl_3) δ 1.13 (s, 3H), 1.63 (brs, 3H), 2.42 (s, 1H), 2.82 (s, 3H), 2.97 (s, 1H), 6.27 (s, 1H), 6.83-6.80 (m, 2H), 6.93 - 6.89 (m, 2H) ppm, one NH-proton remained unsolved

LC-MS (M+H): 252.4

Purity (HPLC): 95.1%

Example 28: N'-(4-fluorophenyl)-1,3-dimethylpyrrolidine-2-carbohydrazide




The title compound was prepared using an analogous procedure as disclosed for Example 16 (method A), employing 1,3-dimethylpyrrolidine-2-carboxylic acid (Intermediate-20) (200 mg, 1.4 mmol) as starting material, which afforded 48 mg of crude product which was purified by column chromatography using 2% MeOH in DCM as eluent to afford 29 mg of the title compound (8% yield).

^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 1.06 (s, 3H), 1.38 (s, 1H), 2.06-2.03 (m, 1H), 2.20 (s, 1H), 2.30 (s, 3H), 2.35 - 2.31 (m, 1H), 3.04 (t, J = 3.8 Hz, 1H), 6.71-6.58 (m, 2H), 7.00-6.96 (m, 2H), 7.63 (s, 1H), 9.63 (s, 1H) ppm;

LC-MS (M+H): 252.4

Purity (HPLC): 96.78%

Example 29: 1-ethyl-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide

5

The title compound was prepared using an analogous procedure as disclosed for Example 16 (method A), employing 1-ethylpyrrolidine-2-carboxylic acid (Intermediate-21) (100 mg, 0.70 mmol) as starting material, which afforded 30 mg of crude product which was purified by column chromatography using 9.5:0.5 (v/v) MeOH:DCM as eluent to yield 30 mg of the title compound (17% yield).


10

^1H NMR (500 MHz, CDCl_3) δ 1.17 (t, J = 7.2 Hz, 3H), 1.88-1.85 (m, 2H), 1.96 (d, J = 4.0 Hz, 1H), 2.22-2.20 (m, 1H), 2.45 (brs, 1H), 2.62 (s, 1H), 2.78 (t, J = 7.3 Hz, 1H), 3.24 (d, J = 6.5 Hz, 1H), 3.31 (s, 1H), 6.11 (s, 1H), 6.79-6.69 (m, 2H), 6.95 - 6.90 (m, 2H), 9.21 (brs, 1H) ppm

15

LC-MS (M+H): 252.5


Purity (HPLC): 96.45%

Example 30: 2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboximidamide hydrochloride

20

The title compound was prepared according to the general method B (Scheme II) by coupling N-Cbz protected pyrrolidine-2-carboxylic acid (Intermediate-22) with N-Boc protected 4-fluorophenylhydrazine, followed by deprotection of the N-atom of the pyrrolidine, introduction of the amidine group, and removal of the remaining protecting groups, according to the process depicted in Scheme XI:

25



SCHEME XI

5 *Step 1: Preparation of benzyl 2-(2-(tert-butoxycarbonyl)-2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxylate*

To a stirred solution of 1-(benzyloxycarbonyl)pyrrolidine-2-carboxylic acid (Intermediate-22) (1 g, 4.01 mmol) in DMF (15 mL) DIPEA (1.55 g, 12.01 mmol), HATU (1.9 g, 5.0 mmol) and *tert*-butyl 1-(4-fluorophenyl)hydrazinecarboxylate (1.15 g, 4.38 mmol) were added at 0 °C and the reaction mixture was stirred at room temperature for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was poured into ice-cold water (25 mL) and extracted with EtOAc (2x25 mL). The combined organic layer was washed with water (15 mL) and brine (15 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound (500 mg, 27% yield) as pale yellow semi-solid.

20 *Step 2: Preparation of tert-butyl 1-(4-fluorophenyl)-2-(pyrrolidine-2-carbonyl)hydrazinecarboxylate*

To a stirred solution of 2-(2-(*tert*-butoxycarbonyl)-2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxylic acid (500 mg, 1.09 mmol) in

MeOH (10 mL) Pd/C (10% wet, 100 mg 20% wt/wt) was added and the reaction mixture was stirred under hydrogen atmosphere at room temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was filtered through a pad of celite; and the filtrate was evaporated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 100-200 mesh) to afford the title compound (200 mg, 28% yield) as off white solid.

^1H NMR (400 MHz, DMSO- d_6) δ 10.42 (s, 1H), 7.34 (q, $J=3.8\text{Hz}$, 2H), 7.16-7.11 (m, 2H), 3.62 (q, $J=3.1\text{Hz}$, 1H), 2.83 (t, $J=6.5\text{ Hz}$, 2H), 1.98-1.94 (m, 1H), 1.76-1.70 (m, 2H), 1.67-1.57 (m, 2H), 1.38 (s, 9H)

LC-MS m/z (M+H): 324.11

Step 3: Preparation of tert-butyl 2-(1-(N,N'-bis(tert-butoxycarbonyl)carbamimidoyl)pyrrolidine-2-carbonyl)-1-(4-fluorophenyl)hydrazinecarboxylate

To a stirred solution of *tert*-butyl 1-(4-fluorophenyl)-2-(pyrrolidine-2-carbonyl)hydrazinecarboxylate (300 mg, 0.928 mmol) in DMF (3 mL) 1,3-bis(*tert*-butoxycarbonyl)-2-methyl-2-thiopseudourea (294 mg, 1.01 mmol), TEA (234 mg, 2.314 mmol), and HgCl_2 (251 mg, 0.926 mmol) were added at 0 °C and the reaction mixture was stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC. The reaction mixture was poured into water (20 mL), extracted with EtOAc (2x10 mL). The combined organic layer was washed with water (5 mL) and brine (5 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel, 60-120 mesh) to afford the title compound (200 mg, 38% yield) as white solid.

LC-MS (M+H): 566.3

Step 4: Preparation of 2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboximidamide hydrochloride

A solution of *tert*-butyl 2-(1-(N,N'-bis(*tert*-butoxycarbonyl)carbamimidoyl)pyrrolidine-2-carbonyl)-1-(4-fluorophenyl)hydrazinecarboxylate (200 mg, 0.35 mmol) in 1,4-dioxane.HCl (4 mL) was stirred at room temperature for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure; the residue was co-distilled with DCM to afford the title compound (25 mg, 26% yield) as pale yellow liquid.

¹H NMR (400 MHz, DMSO-*d*₆) δ 9.92 (s, 1H), 7.32 (s, 4H), 6.96 (t, *J*=8.8Hz, 2H), 6.73 (q, *J*=4.2Hz, 2H), 4.62 (d, *J*=6.2Hz, 1H), 3.69-3.61 (m, 2H), 3.54-3.50 (m, 2H), 3.42 (q, *J*=7Hz, 2H)

LC-MS *m/z* (M+H): 301.75

5 Purity (HPLC): 94.0%

Example 31: Antimicrobial activity

The products of the present invention were tested for their activity against *Acinetobacter baumannii* (*A. baumannii*) as well as against the following
10 bacteria: *Staphylococcus aureus* (*S. aureus*), *Streptococcus pneumoniae* (*S. pneumoniae*), *Enterococcus faecium* (*E. faecium*), *Pseudomonas aeruginosa* (*P. aeruginosa*), *Klebsiella pneumoniae* (*K. pneumoniae*) and *Escherichia coli* (*E. coli*).

Minimal inhibitory concentrations (MICs) were determined using a standard microtiter dilution method, according to the Clinical and Laboratory Standards
15 Institute (CLSI) procedures, in particular according to M07-A9: "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - Ninth Edition".

Briefly, compounds were dissolved with dimethyl sulfoxide (DMSO) at 12.8 mg/mL. Serial two-fold dilutions of compounds were performed in DMSO and 1 µl
20 of each dilution were transferred into microtiter culture plates, followed by 100 µl of inoculated culture media to give a final microorganism concentration of 5×10⁵ colony-forming units/mL. Plates were incubated at 37° C for 24 hours and MICs determined as the lowest compound concentration that inhibited growth. Media used in determinations were Cation adjusted Mueller-Hinton Broth for all the microorganisms except for *S.*
25 *pneumoniae* and *E. faecium* whose culture media were supplemented with 2.5% of lysed horse blood. Incubations were performed at air atmosphere except *S. pneumoniae* cultures that were incubated with 5% CO₂ atmosphere.

The MIC values found (in µg/mL) for the tested compounds are given in Table 1 below.

30 TABLE 1

Ex.	<i>A. baumannii</i>	<i>S. aureus</i>	<i>S. pneumo niae</i>	<i>E. faecium</i>	<i>P. aerugino sa</i>	<i>K. pneumo niae</i>	<i>E. coli</i>
2	4	>128	>128	>128	>128	>128	>128

Ex.	<i>A. baumannii</i>	<i>S. aureus</i>	<i>S. pneumoniae</i>	<i>E. faecium</i>	<i>P. aeruginosa</i>	<i>K. pneumoniae</i>	<i>E. coli</i>
3	4	>128	>128	>128	>128	>128	>128
4	2	>128	>128	>128	>128	>128	>128
7	8	128	>128	>128	>128	>128	>128
9	8	>128	>128	>128	>128	>128	>128
10	2	>128	>128	>128	>128	>128	>128
11	8	>128	>128	>128	>128	>128	>128
14	2	>128	>128	>128	>128	>128	>128
15	1	>128	>128	>128	>128	>128	>128
16	0,25	>128	>128	>128	>128	>128	>128
18	8	128	>128	>128	>128	>128	>128
25	0,25	>128	>128	>128	>128	>128	>128
26	0,25	>128	>128	>128	>128	>128	>128
30	2	>128	>128	>128	>128	>128	>128

As shown in Table 1, compounds of formula (I) according to the present invention are highly effective antibacterials against *A. Baumannii*. Particularly, the MIC values obtained in the assay were of 8 µg/mL or lower for the tested compounds.

- 5 Surprisingly, all the compounds showed a great selectivity for *A. baumannii*, since they were virtually inactive against the other bacteria tested.

Example 32: In vitro stability assay in mouse plasma

- 10 Several compounds of the present invention were tested for their stability in mouse plasma, by LC-MS/MS detection. The concentration of the tested compounds in the assay was 1 µM and the % remaining of each tested compound was calculated at the following time points: 0, 15, 30 and 60 minutes.

- 15 The frozen mouse plasma was thawed at room temperature and centrifuged at 1400x RCF, at 4 °C, for 15 minutes. Approximately 90% of the clear supernatant fraction was transferred to a separate tube and was used for the assay.

1 mM stock of test compound was prepared in acetonitrile:water by diluting from 10 mM stock (i.e. 10 μ L of 10 mM stock solution was added to 90 μ L of acetonitrile: water (50:50)). 25 μ M stock of test compound was prepared in acetonitrile: water by diluting from 1mM stock (i.e. 2.5 μ L of 1mM stock solution was added to 97.5 μ L of acetonitrile: water (50:50)).

For 0 min samples, plasma was heat inactivated at 56 °C. To 72 μ L of heat inactivated plasma 3 μ L of 25 μ M test compound was added. A 50 μ L aliquot of the mixture was taken and crashed with 200 μ L of acetonitrile containing internal standard and was further processed along with other time points.

Final working stock of 1 μ M was prepared by diluting in plasma ((i.e. 10 μ L of 25 μ M acetonitrile:water stock was added to 240 μ L of plasma). 250 μ L of plasma containing the test compound was incubated for 60 min at 37 °C in shaker water bath with gentle shaking. 50 μ L aliquot of sample at 15, 30 and 60 min was precipitated immediately with 200 μ L of acetonitrile containing internal standard and centrifuged at 4000x RCF, 4 °C for 20 minutes. 150 μ L of supernatant was diluted with 150 μ L of water and analyzed by LC-MS/MS.

The percent remaining of the test substance was calculated as ratio of peak area at each time point to peak area ratio at zero min, multiplied by 100.


The LC/MS/MS method used is defined by the following parameters:
API4000 (MS), Shimadzu Prominence (LC), 20 μ L injection volume; Column: Waters Xbridge, C18, 50* 4.6 mm, 3.5 μ m; eluent A: 0.1% formic acid in water, eluent B: acetonitrile; gradient: 0-0.80 min 95% A, 5% B; 0.08-1.6 min 5% A, 95% B; 1.6-2.5 min 95% A, 5% B; flow rate: 1mL ml/min.

The compounds of formula (I) were found highly stable in this assay, with percentages remaining in the mouse plasma after 1 hour of 80% or superior, in most cases of more than 90%.

This data is highly relevant for the use of the compounds of the present invention as drugs, since a long stability in plasma is desirable to obtain good pharmacokinetic exposure of the drug and to maintain the activity *in-vivo* and is therefore significant in order to achieve a good therapeutic antibacterial efficacy.

CLAIMS

1.- A compound of formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof,

wherein

R_1 and R_2 are independently selected from hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl and hydroxy C_{1-4} alkyl;

- 10 R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkoxy, halo C_{1-4} alkoxy, $-OC_{3-6}$ cycloalkyl C_{0-4} alkyl, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{1-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-OCOR_{11}$, $-OS(O_2)R_{11}$, $-NR_{11}R_{12}$, $-NR_{11}COR_{12}$, $-NR_{11}CO_2R_{12}$, $-NR_{11}S(O_2)R_{12}$, $-OCONR_{11}R_{12}$, $-CONR_{11}R_{12}$, $-S(O_2)NR_{11}R_{12}$, $-S(O_2)R_{11}$, $-CN$ and $-CO_2R_{11}$; or two of R_3 to R_7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl or halo C_{1-4} alkyl;

- 15 R_8 is selected from $-OH$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-C(O)C_{3-6}$ cycloalkyl C_{0-2} alkyl, $-CONR_{13}R_{14}$, $-C(NR_{15})NR_{11}R_{12}$ and $-CO_2R_{11}$;

R_9 is selected from hydrogen, C_{1-4} alkyl and halo C_{1-4} alkyl;

n is 0, 1, 2 or 3;

- each R_{10} , if present, is independently selected from $-OH$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-4} alkoxy C_{1-6} alkyl, $-OC_{3-6}$ cycloalkyl C_{0-4} alkyl, $-SR_{11}$, $-NR_{11}R_{12}$, $-OCOR_{11}$, $-OS(O_2)R_{11}$, $-NR_{11}COR_{12}$, $-NR_{11}CO_2R_{12}$, $-NR_{11}S(O_2)R_{12}$, $-OCONR_{11}R_{12}$, $-CN$, phenyl, 5- or 6-membered heteroaryl ring comprising 1 or 2 heteroatoms selected from N, O and S; wherein said phenyl and said heteroaryl ring may be optionally substituted by one or more C_{1-4} alkyl or halo C_{1-4} alkyl; or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to a common carbon atom form a spiro C_{3-6} cycloalkyl, or two R_{10} attached to adjacent carbon atoms are connected to form a 3-

- to 6-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl, haloC₁₋₄alkyl and halogen;
 each R₁₁ and R₁₂ are independently selected from hydrogen, C₁₋₄alkyl, haloC₁₋₄alkyl and C₃₋₆cycloalkylC₀₋₄alkyl;
- 5 each R₁₃ and R₁₄ are independently selected from hydrogen, C₁₋₄alkyl, C₃₋₆cycloalkylC₀₋₄alkyl and Het₃₋₆, wherein each C₁₋₄alkyl and C₃₋₆cycloalkylC₀₋₄alkyl may optionally be substituted by one or more R₁₆, and wherein each C₁₋₄alkyl may optionally be substituted by one or more Het₃₋₆; or R₁₃ and R₁₄ form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can
- 10 optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl, haloC₁₋₄alkyl and C₂₋₅acyl;
 R₁₅ is selected from hydrogen, C₁₋₆alkyl, haloC₁₋₆alkyl, -CN, -CONR₁₁R₁₂, -S(O₂)R₁₁, -SOR₁₁ and -S(O₂)NR₁₁R₁₂;
- 15 each R₁₆ is independently selected from alkyl, halogen, -CN, -CO₂R₁₁, -OR₁₁, -SR₁₁, -NR₁₇R₁₈, -CONR₁₇R₁₈ and -OCOR₁₁;
 Het₃₋₆ is a 3- to 6-membered saturated monocyclic heterocyclic ring containing one heteroatom selected from O, S and N, wherein said ring is bonded to the rest of the molecule through any available C atom and wherein said ring can be optionally
- 20 substituted by one or more substituents independently selected from C₁₋₄alkyl or haloC₁₋₄alkyl; and
 each R₁₇ and R₁₈ are independently selected from hydrogen, C₁₋₄alkyl and haloC₁₋₄alkyl, or R₁₇ and R₁₈ form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional
- 25 heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C₁₋₄alkyl and haloC₁₋₄alkyl;
 and wherein the following products are excluded:
tert-butyl (S)-2-(2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxylate,
tert-butyl (R)-2-(1-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxylate,
 30 *tert*-butyl (2S,4S)-4-mercapto-2-(2-(3-sulfamoylphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate,
 3-(2-((2S,4S)-1-(*tert*-butoxycarbonyl)-4-mercaptopyrrolidine-2-carbonyl)hydrazinyl)benzoic acid,
tert-butyl (2S,4S)-4-mercapto-2-(2-(2-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxylate, and
- 35

tert-butyl (2*S*,4*S*)-2-(2-(2-chloro-5-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)-4-mercaptopyrrolidine-1-carboxylate

2.- A compound according to claim 1, wherein

- 5 R_1 and R_2 are independently selected from hydrogen and C_{1-4} alkyl;
 R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, $-NR_{11}R_{12}$, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-CONR_{11}R_{12}$, $-SO_2-NR_{11}R_{12}$, and halo C_{1-4} alkoxy, or two of R_3 to R_7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered
10 cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl;
 R_8 is selected from $-OH$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-C(O)C_{3-6}$ cycloalkyl C_{0-2} alkyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$;
15 R_9 is selected from hydrogen and C_{1-4} alkyl;
 n is 0, 1, 2 or 3;
each R_{10} , if present, is independently selected from $-OH$, halogen, C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, $-SR_{11}$ and $-NR_{11}R_{12}$; or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3-
20 to 6-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and halogen;
each R_{11} and R_{12} are independently selected from hydrogen and C_{1-4} alkyl;
each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-membered
25 saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-5} acyl; and
 R_{15} is selected from hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, $-CN$, $-CONR_{11}R_{12}$, $-SO_2-R_{11}$, $-SO-R_{11}$ and $-SO_2-NR_{11}R_{12}$.

30

3.- A compound according to claims 1 or 2, wherein at least one of R_3 to R_7 is not hydrogen and at least two of R_3 to R_7 are hydrogen.


- 4.- A compound according to any of claims 1 to 3, wherein R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-4} alkoxy C_{0-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy.
- 5 5.- A compound according to claim 4, wherein R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, halogen, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy.
- 6.- A compound according to claim 5, wherein R_5 is selected from halogen, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, $-SO_2-NR_{11}R_{12}$ and halo C_{1-4} alkoxy; R_3 is selected from hydrogen, halogen and C_{1-4} alkyl; and R_4 , R_6 and R_7 are hydrogen.
- 10 7.- A compound according to claims 1 or 2, wherein R_4 and R_5 are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl, and R_3 , R_6 and R_7 are hydrogen.
- 15 8.- A compound according to any of claims 1 to 7, wherein R_1 , R_2 and R_9 are hydrogen.
- 20 9.- A compound according to any of claims 1 to 8 wherein R_8 is selected from $-OH$, C_{1-4} alkyl, C_{3-6} cycloalkyl C_{1-4} alkyl, C_{2-5} acyl, $-CONR_{13}R_{14}$ and $-C(NR_{15})NR_{11}R_{12}$; wherein each R_{13} and R_{14} are independently selected from hydrogen and C_{1-4} alkyl, or R_{13} and R_{14} form, together with the N atom to which they are attached, a 6-membered saturated heterocycle, which contains one additional heteroatom selected from N and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and C_{2-3} acyl.
- 25 10.- A compound according to any of claims 1 to 9, wherein n is 1 or 2 and each R_{10} is independently selected from halogen, C_{1-4} alkyl and $-NR_{11}R_{12}$; or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 5-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and halogen.
- 30 11.- A compound according to any of claims 1 to 9, wherein n is 0.
- 35

12.- A compound according to claim 1, which is selected from the group consisting of:

- N'-(4-fluorophenyl)-1,5-dimethylpyrrolidine-2-carbohydrazide
- (*R*)-2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 5 – (*S*)-2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-fluoro-2-methylphenyl)hydrazine-1-carbonyl)pyrrolidine-1-carboxamide
- 2-(2-(3,5-difluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-(trifluoromethoxy)phenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 10 – 2-(2-(4-(trifluoromethyl)phenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-chloro-2-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 2-(2-(4-methoxyphenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 2-(2-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- 15 – 2-(2-(4-sulfamoylphenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- (2*S*,4*S*)-4-fluoro-2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboxamide
- (*R*)-1-acetyl-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-1-hydroxypyrrolidine-2-carbohydrazide
- 20 – N'-(4-fluorophenyl)-1,2-dimethylpyrrolidine-2-carbohydrazide
- 2-(2-(4-fluorophenyl)hydrazinecarbonyl)-N,N-dimethylpyrrolidine-1-carboxamide
- N'-(4-fluorophenyl)-1-(piperazine-1-carbonyl)pyrrolidine-2-carbohydrazide
- 1-(4-acetylpiperazine-1-carbonyl)-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide
- 25 – N'-(4-fluorophenyl)-1-(morpholine-4-carbonyl)pyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-1-methyl-5-oxopyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide
- 4-amino-N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide
- 4-fluoro-N'-(4-fluorophenyl)-1-methylpyrrolidine-2-carbohydrazide
- 30 – (*S*)-1-(cyclopropylmethyl)-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-3-methyl-3-azabicyclo[3.1.0]hexane-2-carbohydrazide
- N'-(4-fluorophenyl)-1,4-dimethylpyrrolidine-2-carbohydrazide
- N'-(4-fluorophenyl)-1,3-dimethylpyrrolidine-2-carbohydrazide
- 1-ethyl-N'-(4-fluorophenyl)pyrrolidine-2-carbohydrazide

– 2-(2-(4-fluorophenyl)hydrazinecarbonyl)pyrrolidine-1-carboximidamide
or a pharmaceutically acceptable salt, or solvate thereof.

13.- A compound of formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof,

wherein

R_1 and R_2 are independently selected from hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl and hydroxy C_{1-4} alkyl;

R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkoxy, halo C_{1-4} alkoxy, $-OC_{3-6}$ cycloalkyl C_{0-4} alkyl, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{1-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-OCOR_{11}$, $-OS(O_2)R_{11}$, $-NR_{11}R_{12}$, $-NR_{11}COR_{12}$, $-NR_{11}CO_2R_{12}$, $-NR_{11}S(O_2)R_{12}$, $-OCONR_{11}R_{12}$, $-CONR_{11}R_{12}$, $-S(O_2)NR_{11}R_{12}$, $-S(O_2)R_{11}$, $-CN$ and $-CO_2R_{11}$; or two of R_3 to R_7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl or halo C_{1-4} alkyl;

R_8 is selected from $-OH$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-C(O)C_{3-6}$ cycloalkyl C_{0-2} alkyl, $-CONR_{13}R_{14}$, $-C(NR_{15})NR_{11}R_{12}$ and $-CO_2R_{11}$;

R_9 is selected from hydrogen, C_{1-4} alkyl and halo C_{1-4} alkyl;

n is 0, 1, 2 or 3;

each R_{10} , if present, is independently selected from $-OH$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-4} alkoxy C_{1-6} alkyl, $-OC_{3-6}$ cycloalkyl C_{0-4} alkyl, $-SR_{11}$, $-NR_{11}R_{12}$, $-OCOR_{11}$, $-OS(O_2)R_{11}$, $-NR_{11}COR_{12}$, $-NR_{11}CO_2R_{12}$, $-NR_{11}S(O_2)R_{12}$, $-OCONR_{11}R_{12}$, $-CN$, phenyl, 5- or 6-membered heteroaryl ring comprising 1 or 2 heteroatoms selected from N, O and S; wherein said phenyl and said heteroaryl ring may be optionally substituted by one or more C_{1-4} alkyl or halo C_{1-4} alkyl; or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to a common carbon atom form a spiro

C_{3-6} cycloalkyl, or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl, halo C_{1-4} alkyl and halogen; each R_{11} and R_{12} are independently selected from hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl and C_{3-6} cycloalkyl C_{0-4} alkyl;

5 each R_{13} and R_{14} are independently selected from hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl and Het $_{3-6}$, wherein each C_{1-4} alkyl and C_{3-6} cycloalkyl C_{0-4} alkyl may optionally be substituted by one or more R_{16} , and wherein each C_{1-4} alkyl may optionally be substituted by one or more Het $_{3-6}$; or R_{13} and R_{14} form, together with the N atom to

10 which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl, halo C_{1-4} alkyl and C_{2-5} acyl;

R_{15} is selected from hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, $-CN$, $-CONR_{11}R_{12}$, $-S(O_2)R_{11}$, $-SOR_{11}$ and $-S(O_2)NR_{11}R_{12}$;

15 each R_{16} is independently selected from alkyl, halogen, $-CN$, $-CO_2R_{11}$, $-OR_{11}$, $-SR_{11}$, $-NR_{17}R_{18}$, $-CONR_{17}R_{18}$ and $-OCOR_{11}$;

Het $_{3-6}$ is a 3- to 6-membered saturated monocyclic heterocyclic ring containing one heteroatom selected from O, S and N, wherein said ring is bonded to the rest of the

20 molecule through any available C atom and wherein said ring can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl or halo C_{1-4} alkyl; and

each R_{17} and R_{18} are independently selected from hydrogen, C_{1-4} alkyl and halo C_{1-4} alkyl, or R_{17} and R_{18} form, together with the N atom to which they are attached, a 4- to


25 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and halo C_{1-4} alkyl;

for use as a medicament.

30 14.- A compound according to any of claims 2 to 12 for use as a medicament.

15.- A compound for use according to claims 13 or 14, for use as antibacterial agent, preferably for treating or preventing *A. baumannii* infections.

35 16.- A pharmaceutical composition comprising a compound of formula (I):



(I)


or a pharmaceutically acceptable salt or solvate thereof,

wherein


- 5 R_1 and R_2 are independently selected from hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl and hydroxy C_{1-4} alkyl;
 R_3 , R_4 , R_5 , R_6 and R_7 are independently selected from hydrogen, $-OH$, halogen, C_{1-6} alkoxy, halo C_{1-4} alkoxy, $-OC_{3-6}$ cycloalkyl C_{0-4} alkyl, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-4} alkoxy C_{1-6} alkyl, C_{1-4} alkoxy C_{1-4} alkoxy, $-OCOR_{11}$,
- 10 $-OS(O_2)R_{11}$, $-NR_{11}R_{12}$, $-NR_{11}COR_{12}$, $-NR_{11}CO_2R_{12}$, $-NR_{11}S(O_2)R_{12}$, $-OCONR_{11}R_{12}$, $-CONR_{11}R_{12}$, $-S(O_2)NR_{11}R_{12}$, $-S(O_2)R_{11}$, $-CN$ and $-CO_2R_{11}$; or two of R_3 to R_7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl may be replaced by O, said cycloalkyl can be optionally substituted by one or more C_{1-4} alkyl or halo C_{1-4} alkyl;
- 15 R_8 is selected from $-OH$, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkoxy C_{0-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl, C_{2-5} acyl, $-C(O)C_{3-6}$ cycloalkyl C_{0-2} alkyl, $-CONR_{13}R_{14}$, $-C(NR_{15})NR_{11}R_{12}$ and $-CO_2R_{11}$;
 R_9 is selected from hydrogen, C_{1-4} alkyl and halo C_{1-4} alkyl;
 n is 0, 1, 2 or 3;
- 20 each R_{10} , if present, is independently selected from $-OH$, halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-4} alkoxy C_{1-6} alkyl, $-OC_{3-6}$ cycloalkyl C_{0-4} alkyl, $-SR_{11}$, $-NR_{11}R_{12}$, $-OCOR_{11}$, $-OS(O_2)R_{11}$, $-NR_{11}COR_{12}$, $-NR_{11}CO_2R_{12}$, $-NR_{11}S(O_2)R_{12}$, $-OCONR_{11}R_{12}$, $-CN$, phenyl, 5- or 6-membered heteroaryl ring comprising 1 or 2 heteroatoms selected from N, O and S; wherein said phenyl and said heteroaryl ring may be optionally
- 25 substituted by one or more C_{1-4} alkyl or halo C_{1-4} alkyl; or two R_{10} attached to a common carbon atom form an oxo; or two R_{10} attached to a common carbon atom form a spiro C_{3-6} cycloalkyl, or two R_{10} attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, said cycloalkyl can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl, halo C_{1-4} alkyl and halogen;

- each R_{11} and R_{12} are independently selected from hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl and C_{3-6} cycloalkyl C_{0-4} alkyl;
- each R_{13} and R_{14} are independently selected from hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl C_{0-4} alkyl and Het $_{3-6}$, wherein each C_{1-4} alkyl and C_{3-6} cycloalkyl C_{0-4} alkyl may optionally be substituted by one or more R_{16} , and wherein each C_{1-4} alkyl may optionally be substituted by one or more Het $_{3-6}$; or R_{13} and R_{14} form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl, halo C_{1-4} alkyl and C_{2-5} acyl;
- R_{15} is selected from hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, $-CN$, $-CONR_{11}R_{12}$, $-S(O_2)R_{11}$, $-SOR_{11}$ and $-S(O_2)NR_{11}R_{12}$;
- each R_{16} is independently selected from alkyl, halogen, $-CN$, $-CO_2R_{11}$, $-OR_{11}$, $-SR_{11}$, $-NR_{17}R_{18}$, $-CONR_{17}R_{18}$ and $-OCOR_{11}$;
- Het $_{3-6}$ is a 3- to 6-membered saturated monocyclic heterocyclic ring containing one heteroatom selected from O, S and N, wherein said ring is bonded to the rest of the molecule through any available C atom and wherein said ring can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl or halo C_{1-4} alkyl; and
- each R_{17} and R_{18} are independently selected from hydrogen, C_{1-4} alkyl and halo C_{1-4} alkyl, or R_{17} and R_{18} form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C_{1-4} alkyl and halo C_{1-4} alkyl;
- and at least one pharmaceutically acceptable excipient and/or carrier.

17.- A process for the preparation of a compound of claim 1, comprising reacting a compound of formula (II)



- with a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof



(III)

wherein R₁₆ is hydrogen or a C₁₋₄alkyl, R₁₇ is hydrogen or R₈, and n and R₁ to R₁₅ have the same meaning as described in claim 1.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/069179

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D403/06 C07D405/12 C07D413/06 C07D211/36 C07D211/40 C07D211/94 A61K31/5375 A61K31/4025 A61K31/40 A61K31/396 A61P31/04		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, CHEM ABS Data, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2016/016291 A1 (FERRER INT [ES]) 4 February 2016 (2016-02-04) cited in the application Same core scheme - pyridinone ring instead of a pyrrolidine ring; claims 1-30 -----	1-17
A	GB 769 482 A (LEPETIT SPA) 6 March 1957 (1957-03-06) the whole document -----	1-17
A	WO 2013/153394 A1 (REDX PHARMA LTD [GB]) 17 October 2013 (2013-10-17) the whole document -----	1-17
-/-		
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
19 September 2017		04/10/2017
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Sotoca Usina, E

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2017/069179

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2012/051708 A1 (UNIV BRITISH COLUMBIA [CA]; UNIV FRASER SIMON [CA]; REINER NEIL E [CA]) 26 April 2012 (2012-04-26) the whole document -----	1-17
A	CN 101 525 336 A (SHANDONG XUANZHU MEDICINE TECH) 9 September 2009 (2009-09-09) Disclaimed Intermediates of Formula II for the preparation of compounds of pages 10-11 -----	1
A	Longbin Liu et al: "Structure-Based Design of Novel Class II c-Met Inhibitors: 2. SAR and Kinase Selectivity Profiles of the Pyrazolone Series", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 5, 8 March 2012 (2012-03-08), pages 1868-1897, XP055407406, ISSN: 0022-2623, DOI: 10.1021/jm201331s Disclaimed compounds 29a, 32a -----	1
A	Martin Völkert et al: "Phenylhydrazide as an Enzyme-Labile Protecting Group in Peptide Synthesis", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 67, no. 20, 1 October 2002 (2002-10-01), pages 6902-6910, XP055407404, ISSN: 0022-3263, DOI: 10.1021/jo0259966 Disclaimed compound 6 -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2017/069179

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016016291	A1	04-02-2016	
		AU 2015295380 A1	02-02-2017
		CA 2955559 A1	04-02-2016
		CN 106660962 A	10-05-2017
		EP 3174852 A1	07-06-2017
		JP 2017523197 A	17-08-2017
		KR 20170038822 A	07-04-2017
		PE 04302017 A1	13-04-2017
		PH 12017500057 A1	15-05-2017
		US 2017217887 A1	03-08-2017
		WO 2016016291 A1	04-02-2016

GB 769482	A	06-03-1957	NONE

WO 2013153394	A1	17-10-2013	NONE

WO 2012051708	A1	26-04-2012	NONE

CN 101525336	A	09-09-2009	NONE
